Clinical trial NCT02779777
Conditions: Myelodysplastic Syndromes
Sponsor: Kura Oncology, Inc.
Start date: 2016-06-01; Completion date: 2018-08-28
Enrollment: 16 participants; Allocation: RANDOMIZED; Intervention model: SINGLE_GROUP

Brief summary:
This is a Phase 2 randomized, open-label, two-stage study designed to investigate the antitumor activity of tipifarnib in approximately 36 eligible subjects with MDS who have no known curative treatment. Subjects will be randomized to receive tipifarnib orally with food according to one of 2 treatment regimens.

Detailed description:
This Phase 2 study will investigate the antitumor activity in terms of ORR of tipifarnib in approximately 36 eligible subjects with MDS who have no known curative treatment. Eligible subjects may have received no more than 2 prior systemic regimens. Subjects will be randomized to receive tipifarnib orally with food according to one of 2 dose regimens. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment until disease progression.

Disease assessments will be performed at screening and at least once every approximately 12 weeks starting at the end of cycle 3. Determination of ORR will be assessed by the Investigator according to the MDS International Working Group (IWG) criteria (Cheson 2006). Upon disease progression, all subjects in the study will be followed approximately every 12 weeks for survival and the use of subsequent therapy until either death or 12 months after accrual of the study has been completed, whichever occurs first.

Arms: arm 1: 600 mg twice daily (bid) for 7 days on Days 1-7 in 28 day cycles. arm 2: 300 mg bid for 21 days on Days 1-21 in 28 day cycles.
Interventions: intervention 1: Tipifarnib
Intervention descriptions: intervention 1: Oral tablet

Protocol documents:
Prot_000.pdf: 
Protocol Number: KO‐TIP‐003 
 
Official Title: An Adaptive Phase 2 Study of Tipifarnib in Subjects with Myelodysplastic Syndromes 
 
NCT Number: NCT02779777 
 
Document Date: 19 July 2017 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 1 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
 
 
 
 
CLINICAL TRIAL PROTOCOL 
 
An Adaptive Phase 2 Study of Tipifarnib in Subjects with Myelodysplastic 
Syndromes 
 
CTP ID Number: KO-TIP-003 
Investigational Product: Tipifarnib (R115777; Zarnestra™) 
US IND Number: 052,302 
EudraCT Number: 
Indication: Advanced Hematological Malignancies 
Development Phase: Phase 2 
 
Sponsor: Kura Oncology, Inc. 
3033 Science Park Drive, Suite 220 
San Diego, CA 92921 (USA) 
Phone: +1 858.500.8800  
 
Protocol Author: 
   
Version and Date: Protocol Amendment 3, 09 July 2017 
 
 
CONFIDENTIAL 
This is a Kura Oncology, Inc. document that contains confidential information. It is intended solely for the 
recipient clinical Investigator(s) and must not be disclosed to any other party. This material may be used only 
for evaluating or conducting clinical investigations; any other proposed use requires written consent from Kura 
Oncology, Inc. 
 




Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 3 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
2 
SYNOPSIS 
TITLE: An Adaptive Phase 2 Study of Tipifarnib in Subjects with Myelodysplastic Syndromes 
SPONSOR: Kura Oncology, Inc. 
PROTOCOL NUMBER: KO-TIP-003 
STUDY SITES: One or more clinical centers in the United States  
PHASE OF DEVELOPMENT: Phase 2 
STUDY PERIOD: This study is planned to initiate enrollment in the first half of 2016. It is 
estimated that it may require approximately 24 months to complete all of the study objectives. 
OBJECTIVES: 
Primary Objective: To assess the antitumor activity of tipifarnib in terms of overall response 
rate (ORR) in subjects with myelodysplastic syndromes (MDS). 
Secondary Objective 1:  To assess the effect of tipifarnib on the following: 
• Rate of Transfusion Indepenence 
• Duration of Transfusion Independence 
• Hematologic Improvement 
• Duration of Response 
• Rate of progression free survival (PFS) at 1 year 
• Rate of survival at 1 year 
• Safety and tolerability  
Secondary Objective 2: To evaluate the activity of tipifarnib in subjects treated with two 
different tipifarnib dose regimens (regimen 1 and regimen 2). 
 
 
 
  
 
 
  
 
 
STUDY DESIGN: 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 4 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
This phase 2 study will investigate the antitumor activity in terms of ORR of tipifarnib in 
approximately 36 eligible subjects with MDS who have no known curative treatment.  Eligible 
subjects may have received no more than 2 prior systemic regimens.  Prior systemic regimens are 
those that are considered standard of care for the treatment of MDS, have been received at 
standard doses for at least one full treatment cycle and exclude erythropoiesis-stimulating agents 
(ESA).   
A two-stage study design will be employed in order to minimize the number of study subjects 
treated if tipifarnib were considered not sufficiently efficacious to grant further development in 
this subject population.  In the first stage, 22 eligible subjects will be enrolled and randomized to 
1 of 2 dosing regimens (regimen 1 or regimen 2). If two or more responses are observed in a 
given dose regimen cohort, 7 additional study subjects will be enrolled. 
Subjects will be randomized to receive tipifarnib orally with food, twice a day (bid) according to 
one of the following dose regimens: 
• Regimen 1: 600 mg bid for 7 days on Days 1-7 in 28 day cycles (i.e. 1 week on / 3 weeks 
off).  
At the discretion of the investigator, the dose of tipifarnib may be increased to 800 mg bid if 
the subject has not experienced dose limiting toxicities at the 600 mg dose level. Subjects are 
not to be dose escalated until after completing Cycle 1 to ensure the dosing regimen is 
tolerated prior to escalation.  Stepwise 200 mg dose reductions to control treatment-related, 
treatment-emergent toxicities are also allowed. Subjects who develop serious adverse events 
(SAE), ≥ grade 2 treatment-emergent adverse events (TEAE) that are deemed related to 
tipifarnib and lasting ≥ 14 days will not undergo dose escalation.   
• Regimen 2: 300 mg bid for 21 days on Days 1-21 in 28 day cycles (i.e. 3 weeks on / 1 
week off).  
Stepwise 100 mg dose reductions to control treatment-related, treatment-emergent toxicities 
are allowed. 
Subjects who received a starting dose of 900 mg bid during the conduct of the original version of 
this protocol may be dose reduced to the 600 mg bid dose at the discretion of the investigator 
(Amendment 1).  Subjects who received tipifarnib on Days 1 – 7 and Days 15 – 21 during the 
conduct of the original version and amendment 1 of this protocol, may transition to the new 
treatment administration schedule (tipifarnib on Days 1-7 in 28 day cycles) beginning on Day 1 
of their next cycle. 
In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment 
until disease progression.  If a complete remission (CR) is observed, therapy with tipifarnib will 
be maintained for at least 6 months beyond the start of response.  
Hematologic assessments, including peripheral blood evaluations and review of transfusion 
requirements, will be performed at screening and at least monthly until disease progression.  


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 5 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Disease assessments will also be performed at screening and at least once every approximately 
12 weeks starting at the end of cycle 3.  As part of the disease assessment at screening and during 
Cycles 3, 6 and 9, bone marrow evaluation will be performed.  Thereafter, bone marrow 
evaluations will occur during disease assessments in accordance with institutional standard 
practice.  Additional hematologic or disease assessments may be conducted if deemed necessary 
by the Investigator. The timing of the hematologic and disease assessments should be maintained 
as much as possible independently of potential treatment cycle delays. 
Determination of ORR will be assessed by the Investigator according to the MDS International 
Working Group (IWG) criteria (Cheson 2006, Table 9 and Table 10).   
Upon disease progression, all subjects in the study will be followed approximately every 12 
weeks for survival and the use of subsequent therapy until either death or 12 months after accrual 
of the study has been completed, whichever occurs first. Information on survival and subsequent 
anticancer therapy may be collected by phone. 
Subjects who terminate treatment for reasons other than death or disease progression will be 
assessed at regular intervals for disease progression (approximately every 12 weeks) and 
leukemic transformation (monthly blood counts).  Disease assessments performed during the first 
9 months from the start of the subject’s participation in the study will include bone marrow 
evaluation.  Thereafter, bone marrow evaluations will occur during disease assessments in 
accordance with institutional standard practice.  These assessments will continue until disease 
progression, withdrawal of subject’s consent to study procedures or initiation of another 
anticancer therapy.   
All subjects will be followed-up for safety during treatment and up to approximately 30 days (30 
± 7 days) after treatment discontinuation or until immediately before the initiation of another 
anticancer therapy, whichever occurs first. Additional follow up may be implemented until the 
subject recovers from any emergent treatment related toxicity or the adverse event is considered 
irreversible by the Investigator. Target organ toxicities will be monitored via clinical and 
laboratory assessments using the National Cancer Institute Common Terminology Criteria for 
Adverse Events version 4.03 (NCI CTCAE v 4.03) criteria. 
NUMBER OF SUBJECTS PLANNED: Approximately 36 eligible study subjects. 
SUBJECT SELECTION:  
Inclusion Criteria 
For inclusion of a subject in the study, all of the following inclusion criteria must be fulfilled: 
1. Subject is at least 18 years of age. 
2. Documented pathological evidence of MDS as defined by the World Health Organization 
(WHO) criteria (Table 8). 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 6 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2. 
4. Subjects have no known curative treatment.    
5. Subject is willing and able to comply with scheduled visits, treatment plans, laboratory tests 
and other procedures (including bone marrow assessments). 
6. At least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1.  Subjects 
must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities (excluding 
Grade 2 toxicities that are not considered a safety risk by the Sponsor and Investigator) or 
toxicity must be deemed irreversible by the Investigator. 
7. Acceptable hematological function: 
a. Absolute neutrophil count < 1000/mm3 
b. Platelet count > 20,000/mm3 
8. Acceptable liver function:  
a. Total or direct bilirubin ≤ 1.5 times upper limit of normal (x ULN); does not apply to 
subjects with Gilbert’s syndrome diagnosed as per institutional guidelines. 
b. AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN. 
9. Acceptable renal function with serum creatinine ≤ 1.5 x ULN or a calculated creatinine 
clearance ≥ 60 mL/min using the Cockcroft-Gault or Modification of Diet in Renal Disease 
formulas. 
10. Female subjects must be: 
a. Of non-child-bearing potential (surgically sterilized or at least 2 years post-menopausal); 
or 
b. If of child-bearing potential, subject must use a highly effective method of contraception, 
such as combined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation, progestogen-only hormonal contraception 
associated with inhibition of ovulation, intrauterine device,  intrauterine hormone-
releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence.  
Both females and male subjects with female partners of child-bearing potential must 
agree to use a highly effective method of contraception for 2 weeks prior to screening, 
during, and at least 4 weeks after last dose of trial medication. Female subjects must have 
a negative serum or urine pregnancy test within 72 hours prior to start of trial medication. 
c. Not breast feeding at any time during the study. 
11. Written and voluntary informed consent understood, signed and dated. 
Exclusion Criteria 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 7 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
1. Known prior progression to acute myeloid leukemia (AML), defined by at least 20% blasts in 
the blood or bone marrow. 
2. Myelodysplastic or myeloproliferative syndrome other than MDS. 
3. More than two prior systemic regimens for MDS.  Prior systemic regimens are those that are 
considered standard of care for the treatment of MDS, have been received at standard doses 
for at least one full treatment cycle and exclude ESA.   
4. Prior cytoreductive therapy for blast reduction. 
5. Participation in any interventional study within 1 week or 5 half lives (whichever is longer) 
of Cycle 1 Day 1. 
6. Ongoing treatment with an anticancer agent for MDS not contemplated in this protocol. 
7. Prior treatment (at least 1 full treatment cycle) with a farnesyltransferase inhibitor. 
8. Clinically significant anemia due to iron, B12, or folate deficiencies, or autoimmune or 
hereditary hemolytic anemia, or gastrointestinal bleeding. If marrow stain for iron is not 
available, the transferrin saturation (iron/total iron binding capacity Fe/TIBC) must be >20% 
or serum ferritin must be >100 ng/dL. 
9. Active coronary artery disease requiring treatment, myocardial infarction within the prior 
year, New York Heart Association grade III or greater congestive heart failure, cerebro-
vascular attack within the prior year, or current serious cardiac arrhythmia requiring 
medication except atrial fibrillation. 
10. Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without 
complete recovery. 
11. Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy 
(excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and 
hormonal treatment for castration sensitive prostate cancer).  
12. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known 
infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B 
or hepatitis C. 
13. Subjects who have exhibited allergic reactions to tipifarnib, or structural compounds similar 
to tipifarnib or to its excipients. 
14. Concomitant disease or condition that could interfere with the conduct of the study, or that 
would, in the opinion of the investigator, pose an unacceptable risk to the subject in this 
study.  
15. The subject has legal incapacity or limited legal capacity. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 8 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
16. Significantly altered mental status that would limit the understanding or rendering of 
informed consent and compliance with the requirements of this protocol. Unwillingness or 
inability to comply with the study protocol for any reason. 
STATISTICAL METHODS 
This trial employs a 2-stage design independently for each dose regimen cohort.  In the first 
stage, 22 eligible subjects will be enrolled and randomized to 1 of 2 dosing regimens (regimen 1 
or regimen 2, 11 subjects each).  If two or more responses are observed in a given dose regimen 
cohort, 7 additional study subjects will be enrolled.  
Each dose regimen cohort is designed to test the null hypothesis of ORR less than 10% vs 
alternative hypothesis of ORR rate at least 30%.  At the completion of the study, treatment will 
be considered of further interest if 4 or more subjects in the 18 subject dose regimen cohort 
achieve a response, i.e. the true ORR rate is higher than 10%.  
To determine the total trial size, a response of interest of 30% is assumed. This design provides 
80% power to detect a difference between 10% and 30% ORR at one-sided significance level of 
0.087 at each dose cohort. Using this design, the probability of terminating a cohort at the end of 
stage 1 if the true rate is 10% is 0.697 while the probability of terminating the cohort at the end 
of stage 1 if the true rate is 30% is 0.113. 
 
 






Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 11 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
bid dose at the discretion of the investigator.  Subjects who received tipifarnib on Days 1 – 7 and Days 15 – 21 during the 
conduct of the original version and amendment 1 of this protocol, may transition to the new treatment administration 
schedule (tipifarnib on Days 1-7 in 28 day cycles) beginning on Day 1 of their next cycle. 
31. Site staff should conduct a drug accountability on the returned empty bottles and unused medications.  
32. Tipifarnib administration should occur if the Day 22 visit coincides with a dosing day (e.g. visit occurs on Days 17 - 21 of 
the current cycle) for those subjects randomized to receive dosing on Days 1 – 21. 
 
 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 12 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
3 
TABLE OF CONTENTS 
Section 
 ....................................................................................................... Page 
1 
PROTOCOL APPROVAL PAGE ........................................................2 
2 
SYNOPSIS ...........................................................................................3 
3 
TABLE OF CONTENTS ...................................................................12 
4 
ABBREVIATIONS ............................................................................16 
5 
INTRODUCTION ..............................................................................18 
5.1 
Epidemiology ......................................................................................18 
5.2 
Definition and Classification ..............................................................18 
5.3 
MDS and Autoimmunity ....................................................................19 
5.4 
Treatment ............................................................................................19 
5.5 
Tipifarnib ............................................................................................21 
5.5.1 
Mechanism of Action .........................................................................21 
5.5.2 
Clinical Pharmacology ........................................................................21 
5.5.3 
Clinical Experience in MDS ...............................................................22 
5.6 
Rationale for the Study .......................................................................24 
6 
OBJECTIVES .....................................................................................25 
6.1 
Primary Objectives and Endpoints .....................................................25 
6.2 
Secondary Objectives and Endpoints .................................................25 
6.3 
Exploratory Objective and Endpoints .................................................25 
7 
SUBJECT SELECTION .....................................................................26 
7.1 
Inclusion Criteria ................................................................................26 
7.2 
Exclusion Criteria ...............................................................................27 
8 
TRIAL DESIGN .................................................................................28 
8.1 
Study Design .......................................................................................28 
8.2 
Subject Identification and Replacement of Subjects ..........................30 
8.3 
Assignment to Treatment Groups .......................................................30 
8.4 
Removal of Subjects from Treatment or Assessment .........................31 
8.5 
Premature Discontinuation of the Trial ..............................................32 
8.6 
Definition of End of Study .................................................................32 
9 
TREATMENTS ..................................................................................33 
9.1 
Investigational Product .......................................................................33 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 13 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
9.1.1 
Product Characteristics .......................................................................33 
9.1.2 
Storage and Labeling ..........................................................................33 
9.2 
Treatment Administration ...................................................................34 
9.3 
Treatment Assignment ........................................................................34 
9.4 
Dose Selection ....................................................................................35 
 
 
9.6 
Treatment of Overdose .......................................................................41 
9.7 
Blinding ..............................................................................................41 
9.8 
Treatment Compliance ........................................................................41 
9.9 
Investigational Product Accountability ..............................................41 
9.10 
Return and Disposition of Clinical Supplies ......................................42 
9.11 
Prior and Concomitant Medications ...................................................42 
9.12 
Non-permitted Treatments ..................................................................43 
9.13 
Dietary or Other Protocol Restrictions ...............................................43 
9.14 
Medical Care of Subjects after End of Trial .......................................43 
9.15 
Potential Effects on Reproduction and Development .........................43 
10 
EFFICACY AND SAFETY VARIABLES ........................................44 
10.1 
Efficacy Variables ..............................................................................44 
10.2 
Assessment of Safety ..........................................................................45 
10.3 
Adverse Events ...................................................................................45 
10.4 
Abnormal Laboratory Findings and Other Abnormal 
Investigational Findings ......................................................................47 
10.5 
Serious Adverse Event ........................................................................47 
10.6 
Events that Do Not Meet the Definition of an SAE ...........................48 
10.7 
Events Not to Be Considered as AEs/SAEs .......................................48 
10.8 
Methods of Recording and Assessing Adverse Events ......................48 
10.9 
Adverse Event Reporting Period ........................................................48 
10.10 
Procedure for Reporting Serious Adverse Events ..............................49 
10.11 
Safety Reporting to Health Authorities, Institutional Review 
Boards and Investigators .....................................................................49 
10.12 
Monitoring of Subjects with Adverse Events .....................................50 
10.13 
Pregnancy and In Utero Drug Exposure .............................................50 
10.14 
Laboratory Assessments .....................................................................50 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 14 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
 
 
11 
STUDY PROCEDURES ....................................................................51 
11.1 
Screening and Baseline Assessments .................................................51 
11.2 
Day 1 of Cycle 1 .................................................................................53 
11.3 
Day 1 (± 2 days) of Cycle 2 and every cycle thereafter .....................54 
11.4 
Day 22 (± 5 days) of Cycles 3 and every approximately 12 weeks 
thereafter (e.g. 6, 9, 12, etc.) ...............................................................54 
11.5 
End of Treatment Visit .......................................................................55 
11.6 
Post Treatment Follow up ...................................................................56 
11.6.1 
Subjects who Terminate Treatment for Reasons other than Death 
or Disease Progression ........................................................................56 
11.6.2 
Follow Up after Disease Progression .................................................57 
12 
STATISTICAL METHODS ...............................................................57 
12.1 
Populations .........................................................................................57 
12.1.1 
Efficacy Analysis ................................................................................57 
12.1.2 
Safety Analysis ...................................................................................58 
12.2 
Endpoints ............................................................................................58 
12.2.1 
Efficacy ...............................................................................................58 
12.2.2 
Safety and Tolerability .......................................................................59 
 
 
12.4 
Sample Size Determination ................................................................60 
12.5 
Changes in the Conduct of the Study or Planned Analyses ................61 
13 
ETHICAL AND REGULATORY ASPECTS ...................................62 
13.1 
Responsibilities of the Investigator ....................................................62 
13.2 
Subject Information and Informed Consent .......................................62 
13.3 
Subject Identification and Privacy ......................................................63 
13.4 
Emergency Medical Support and Subject Card ..................................63 
13.5 
Clinical Trial Insurance and Compensation to Subjects .....................64 
13.6 
Institutional Review Board/Independent Ethics Committee ..............64 
13.7 
Communication to Health Authorities ................................................64 
14 
TRIAL MANAGEMENT ...................................................................65 
14.1 
Case Report Form Management .........................................................65 
14.2 
Source Data and Subject Files ............................................................65 




Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 16 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
4 
ABBREVIATIONS 
 
AE 
Adverse event 
ALT 
Alanine Aminotransferase 
AML 
Acute myeloid leukemia 
ANC 
Absolute neutrophil count 
APTT 
Activated partial thromboplastin time 
ASaT 
All subjects as treated 
AST 
Aspartate Aminotransferase 
bid 
Twice a day 
BSC 
Best supportive care 
BUN 
Blood urea nitrogen 
CTCAE 
Common Terminology Criteria for Adverse Events 
CML 
Chronic myeloid leukemia 
CMML 
Chronic myelomonocytic leukemia 
CR 
Complete remission 
CRF 
Case report form 
CSR 
Clinical study report 
CYP450 
Cytochrome P450 
DLT 
Dose limiting toxicity 
ECOG 
Eastern cooperative oncology group 
ESA 
Erythropoiesis stimulating agent 
FAS 
Full analysis set 
FDA 
Food and Drug Administration 
Fe/TIBC 
Iron/Total iron binding capacity 
FTase 
Farnesyl transferase 
GCP 
Good Clinical Practice 
HgB 
Hemoglobin 
HI 
Hematological improvement 
HIPAA 
Health Insurance Portability and Accountability Act 
HIV 
Human immunodeficiency virus 
HLA 
Human leukocyte antigen 
ICF 
Informed consent form 
ICH 
International Conference on Harmonization 
IEC 
Independent Ethics Committee 
INT 
Intermediate 
IP 
Investigational product 
IPSS-R 
Revised international prognostic scoring system 
IRB 
Institutional Review Board 
IST 
Immunosuppressive therapy 
IWG 
International Working Group 
KIR 
Killer cell Immunoglobulin-like receptor 
MDS 
Myelodysplastic syndromes 
MDS-U 
Myelodysplastic syndrome, unclassified  


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 17 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
MeDRA 
Medical Dictionary for Regulatory Activities 
MTD 
Maximum tolerated dose 
NCI 
National Cancer Institute  
NK 
Natural Killer 
PR 
Partial remission 
PFS 
Progression free survival 
PT/INR 
Prothrombin time/international normalized ratio 
RA 
Refractory anemia 
RAEB-1 
Refractory anemia with excess blasts-1 
RAEB-2 
Refractory anemia with excess blasts-2 
RAEB-t 
Refractory anemia with excess blasts in transformation 
RARS 
Refractory anemia with ring sideroblasts 
RBC 
Red blood cell 
RCMD 
Refractory anemia with multilineage dysplasia 
RCUD 
Refractory cytopenia with unilineage dysplasia 
rHuEPO 
Recombinant human erythropoietin 
RN 
Refractory neutropenia 
RT 
Refractory thrombocytopenia 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SGOT 
Serum glutamic oxaloacetic transaminase  
SGPT 
Serum glutamic pyruvic transaminase 
SUSAR 
Suspected Unexpected Serious Adverse Reactions 
TEAE 
Treatment-emergent adverse event 
TI 
Transfusion independence 
ULN 
Upper limit of normal 
v 
Version 
WBC 
White blood cell 
WHO 
World health organization 
 
 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 18 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
5 
INTRODUCTION 
5.1 
Epidemiology 
MDS is typically a disease of the elderly, with a median age at diagnosis of 70 to 75 years. Data 
from the Surveillance Epidemiology and End Results program estimated that the average case 
numbers for the United States, was 5.0 per 100,000 annually for 2008 through 2012. Incidence 
rates were highest among whites and increased with age, e.g. incidence was 0.2 per 100,000 in 
individuals < 40 years of age compared to 59.1 per 100,000 in individuals ≥ 80 years of age 
(National Cancer Institute 2012).  Although cases are rare, MDS may also occur in children.  
MDS is uniformly fatal, even without progression to AML, due to infection and bleeding.  In 
patients with lower risk MDS, it is estimated that approximately 84% of patients die of a MDS-
related death, of which infection (38% of deaths), progression to AML (15% of deaths) and 
hemorrhage (13% of deaths) are the most frequent cause of death (Dayyani 2010).   
5.2 
Definition and Classification 
MDS is a group of clonal hematopoietic disorders defined by molecular lesions in pluripotent 
hematopoietic progenitors, affecting myeloid, erythroid and megakaryocytic lineages. MDS is 
characterized by ineffective hematopoiesis associated with a cellular marrow, morphologic 
abnormalities of myeloid precursors, and a frequent excess of blasts and blood cytopenias 
(anemia, neutropenia, thrombocytopenia). The progression through different stages and ultimate 
transformation to AML is a consequence of the accumulation of genetic lesions over a prolonged 
latency period of MDS evolution (Fenaux 1996).     
Recurring clonal cytogenetic abnormalities in the bone marrow are present in about 50% of the 
cases. The most frequent single chromosome abnormalities encountered in de novo MDS are 
deletion of 5q or 7 and trisomy 8. In secondary MDS, deletion of 7 is observed in approximately 
half of the cases; other single chromosome abnormalities are deletion of 5q or 7q, loss of Y, and 
trisomy 8.  Complex findings (≥3 chromosome abnormalities) are present in approximately 50% 
of all cases (Fenaux 1996). Unlike Philadelphia chromosome positive chronic myeloid leukemia 
(CML), no specific chromosome or gene abnormalities are characteristic of all MDS. 
MDS are classified according to the WHO Classification (Table 8) in the following groups: (1) 
refractory cytopenia with unilineage dysplasia (RCUD) that includes refractory anemia (RA), 
refractory neutropenia (RN), and refractory thrombocytopenia (RT); (2) refractory anemia with 
ringed sideroblasts (RARS); (3) refractory anemia with multilineage dysplasia (RCMD); (4) 
refractory anemia with excess blasts-1 (RAEB-1); (5) refractory anemia with excess blasts-2 
(RAEB-2); (6) myelodysplastic syndrome, unclassified (MDS-U); (7) MDS associated with 
isolated del(5q); and (8) refractory cytopenia of childhood as a group of provisional entities.  The 
WHO classification of MDS are predictive of outcome, overall survival, as well as the lifetime 
risk for leukemic transformation (Swerdlow 2008).  


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 19 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
5.3 
MDS and Autoimmunity 
There is evidence that the pathogenesis of MDS involves, at least in part, a phenomenon of 
autoimmunity (Kook 2001, Maciejewski 2002). The incidence of autoimmunity is increased in 
patients with MDS (Saif 2002). Moreover, some features of MDS overlap with those of aplastic 
anemia and large granular lymphocytic leukemia, two diseases thought to course with 
autoreactive lymphocytes (Barret 2000, Kanchan 2003). Autoimmunity may suppress normal 
hematopoiesis by direct cytotoxicity as well as by release of cytokines, such as interferon and 
tumor necrosis factor that interfere with normal hematopoiesis. The causes for autoimmunity in 
MDS are unknown, but it is conceivable that dysplasia-associated antigens released from dying 
cells might be responsible for evoking an adaptive immune response (Smyth 2006).  Overall, an 
enhanced state of activation of various immune effector cell types and autoimmune disease-like 
characteristics have been associated with early stages of MDS, while tumor cells are still 
predisposed to apoptosis (Kitagawa 1993, Kerbauy 2007). 
Among immune effector cells, NK cells appear to play a key role in early stages of MDS. While 
NK cell function appears to be impaired in high risk MDS (Epling-Burnette 2007), NK cells 
have been shown to be activated, with high expression of perforin and granzyme, and to mediate 
the cytotoxicity of bone marrow precursor cells in low-risk disease (Chamuleau 2009). NK cells 
are specialized lymphocytes that mediate host defense against infective agents and malignant 
transformation through cytokine secretion and cytolytic activity (Wu 2003). Their activity is 
modulated, among other cytoplasmic membrane molecules, by KIRs. KIRs recognize HLA C 
and B epitopes on target cells, thereby regulating NK cell activity. KIR genes are polymorphic 
and two broad haplotypes exist: KIR-haplotype A mainly encode for inhibitory receptors and 
only for one activating (KIR2DS4), whereas the group B haplotype encodes more for activating 
KIRs (KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 und KIR3DS1) (Moesta 2012). An 
overrepresentation of one of these activating receptors, KIR2DS2, has been identified in low risk 
MDS (Serio 2006, Momot 2008, Painter 2011) as well as in a number of autoimmune diseases 
including scleroderma (Momot 2004), ulcerative colitis (Jones 2006), type I diabetes (Van der 
Slik 2003) and Sjogren’s disease (Lowe 2009). An imbalance between KIR2DS2 and its cognate 
inhibitory receptor, KIR2DL2, has also been described to play a role in autoimmunity (Epling-
Burnette 2008). Due to the strong linkage disequilibrium between the KIR2DS2 and KIR2DL2 
genes, individuals with the presence of either KIR2DS2 or KIR2DL2 alone are less common, but 
are increased in autoimmune diseases such as scleroderma and Sjogren’s disease (Salim 2010).  
Together, these data strongly suggest an association between KIR2DS2 and autoimmunity 
(Sugimori 2010, Moesta 2012).  
5.4 
Treatment 
Despite advancements in the treatment of MDS, allogeneic bone marrow transplantation is the 
only cure, but its use is generally restricted to patients less than 55 years of age with an HLA-
identical donor. Attenuated conditioning regimens now extend the age limit to as high as 65 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 20 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
years (Cheson, Bennett 2000; Cheson, Zwiebel 2000; Oosterveld 2000).  In patients who are not 
candidates for bone marrow transplantation, no treatment is curative. Furthermore, there are 
limited therapeutic options, particularly in patients who have progressed on supportive 
erythropoiesis stimulating, immunomodulating or hypomethylating agents.     
The major therapeutic aim for patients with lower risk MDS is hematological improvement with 
therapeutic options including supportive care, low-intensity therapy, high intensity therapy 
and/or participation in a clinical study.  Supportive care for patients with MDS may include RBC 
and/or platelet transfusions, antibiotics, aminocaproic acid or other anti-fibrinolytic agent, iron 
chelation as well as hematopoietic cytokines, e.g. erythropoietin, G-CSF and GM-CSF, for 
refractory symptomatic cytopenias (Greenberg Version 1.2016). 
Low intensity therapy includes the use of low-intensity chemotherapy or biologic response 
modifiers.  The hypomethylating agents, azacytidine and decitabine, are Food and Drug 
Administration (FDA) approved for the treatment of MDS having been shown to decrease the 
risk of leukemic transformation and, in a proportion of patients, to improve survival in 
randomized phase 3 clinical studies (Fenaux 2009, Kaminskas 2005, Kantarjian 2006, Lubbert 
2011, Silverman 2002).  Hypomethylating agents have been evaluated in patients of all risk 
levels of MDS and in some studies, patients with higher risk levels were associated with higher 
response rate, remission duration, time to AML progression and survival benefit; however, there 
are limited data on their use of these agents in lower risk MDS and they have not been shown to 
modify the natural history of patients with lower risk MDS  (Kantarjian 2006, Saba 2004).  
Immunosuppresive therapy (IST), including antithymocyte globulin and cyclosporine, have been 
evaluated as a potential treatment for MDS.  In several studies, IST has been shown to be most 
efficacious in MDS patients with HLA-DR15 histocompatibility type, marrow hypoplasia, 
normal cytogenetics, low risk disease and evidence of a paroxysmal nocturnal hemoglobinuria 
clone (Molldrem 1997, Passweg 2011). 
Lenalidomide is an immunomodulating agent which is FDA approved for use in transfusion 
dependent, low or intermediate-1 risk MDS patients with del(5q) chromosomal abnormality. In a 
phase 2 study which supported the FDA approval of lenalidomide in MDS, RBC TI was 
achieved in 66% of patients with del(5q).  However, approximately half of the patients with 
del(5q) treated with lenalidomide experienced National Cancer Institute Common Toxicity 
Criteria grade 3 or 4 neutropenia or thrombocytopenia early in the course of treatment, with 84% 
requiring a dose reduction for myelosuppression (List 2006).  In contrast, in a similarly designed 
phase 2 study evaluating the efficacy of lenalidomide in patients without del(5q) chromosomal 
abnormality, RBC TI was achieved in 26% of patients (Raza 2008).    


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 21 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
5.5 
Tipifarnib 
Beginning in 1997, tipifarnib was the first specific inhibitor of farnesyl transferase (FTase) to 
enter clinical studies and has been evaluated in over 70 clinical oncology and hematology 
studies.  
Brief information on tipifarnib is presented in this section; more extensive information is 
provided in the Investigator’s Brochure (Tipifarnib Investigator’s Brochure, Edition 13, March 
2017).  
5.5.1 
Mechanism of Action 
Tipifarnib is a potent and selective nonpeptide inhibitor of FTase. FTase is an enzyme that 
couples an isoprenyl group, the 15 carbon farnesyl moiety, to proteins for membrane localization 
including the Ras family of oncoproteins. The Ras family (KRAS, NRAS and HRAS) are among 
the most frequently mutated oncogenes in human cancer.  Although FTase inhibitors were 
originally developed to target Ras mutant cancers, tipifarnib and other FTase inhibitors failed to 
demonstrate significant clinical activity specifically in Ras mutant cancers, likely due to the 
observation that KRAS and NRAS undergo an alternate prenylation, geranylgeranylation, when 
FTase is inhibited (Baines 2011, Takashima 2013).  
The correlative biology of FTase inhibition by tipifarnib has been studied extensively. FTase 
inhibitors likely exert their cytotoxic effects by inhibition of multiple farnesylated proteins in the 
cell that are important for proliferation and survival such as members of the Rho, Rheb and 
CENP families.  In vitro, the concentration resulting in 50% of maximum inhibition values for 
isolated human FTase depends on the nature of its substrate, ranging from 0.86 nM for lamin B, 
a nuclear protein, to 7.9 nM for KRAS.  
Tipifarnib has shown promising signs of clinical activity in a variety of cancers including 
hematological cancers such as AML, MDS and certain lymphomas in multiple clinical trials 
(Martinelli 2008). Defining the patient subset or biomarker-defined subset where tipifarnib 
shows high level of efficacy remains as a key focus in the tipifarnib development program. 
5.5.2 
Clinical Pharmacology 
Tipifarnib is rapidly absorbed after oral administration with maximum plasma concentrations 
observed within 2 to 4 hours after dosing. The absolute bioavailability of tipifarnib under fed 
conditions is 29.3% in cancer patients and similar in healthy subjects. Concomitant intake of a 
high fat meal increases the extent of absorption by an average of 26.8% compared with 
administration under fasting conditions.  
Tipifarnib has an initial fast distribution half-life of about 36 minutes, followed by a dominant 
elimination half-life of about 2.4 hours, and a slower terminal half-life of about 19 hours. 
Tipifarnib does not accumulate with multiple dosing. Linear pharmacokinetics are observed for 
tablets over the dose range of 100 mg through 600 mg. Metabolism and elimination are primarily 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 22 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
hepatic. Steady state is reached within 2 to 3 days, with no evidence of drug accumulation or 
induction of drug metabolism over time. In adults, the apparent oral clearance of tipifarnib is not 
influenced by age, sex, body weight, body surface area or the presence of liver metastases. 
Tipifarnib inhibits FTase activity in human peripheral blood lymphocytes isolated from study 
subjects after doses as low as 100 mg bid.  Following a single 600 mg dose, both total and 
unbound plasma concentrations of tipifarnib over a 12-hour interval exceed those required to 
inhibit farnesylation.  Inhibition of FTase is reversible within 3 to 7 days upon discontinuation of 
tipifarnib administration.  
Increases in tipifarnib bioavailability by 18% to 34% have been consistently observed after its 
administration with food and therefore, tipifarnib has been administered with food throughout 
most of its clinical development program. Importantly, however, the magnitude of the food effect 
is small compared to the variability of pharmacokinetic parameters.  
Pharmacokinetic data suggest that H2 antagonists and proton pump inhibitors do not alter the 
exposure to tipifarnib to a clinically significant extent. Subjects may use proton pump inhibitors 
or H2 antagonists during the treatment portion of this study. However, subjects should be 
instructed to use antacids (magnesium or aluminum containing products) at least 2 hours before 
or after intake of oral study drug. 
Tipifarnib is a substrate for cytochrome P450 (CYP450) enzymes and glucuronosyltransferase. 
Inhibitors of CYP450 enzymes, including azole antifungals and omeprazole, did not reduce the 
clearance of tipifarnib in humans. However, antiepileptic drugs that are potent inducers of 
CYP450 enzymes (e.g. phenytoin, phenobarbital and carbamazepine) reduce plasma 
concentrations of tipifarnib and caution is warranted if concomitant administration of such agents 
is necessary.  Therefore, it is recommended that subjects use non-enzyme-inducing anti-
convulsants (e.g., gabapentin, topiramate, valproate) if necessary while taking tipifarnib.  
In addition, population pharmacokinetic analyses evaluated the influence of various concomitant 
medications on the pharmacokinetics of tipifarnib in clinical studies. Amphotericin, antiemetics, 
5HT3 antagonists (dolasetron, granisetron, ondansetron, and tropisetron), antifungal azoles 
(econazole, fluconazole, itraconazole, ketoconazole, and miconazole), benzodiazepines, 
ciprofloxacin, and corticosteroids appeared to have no discernible impact on the plasma 
concentrations of tipifarnib.  
5.5.3 
Clinical Experience in MDS 
Tipifarnib has been evaluated in 4 clinical studies which enrolled patients with varying risk 
levels of MDS (low, intermediate and high). 
In the first study, 21 patients were treated at dose levels ranging from 300 mg bid to 450 mg bid 
for 21 consecutive days, followed by a 1-week rest. They were diagnosed with RA (n=2), RARS 
(n=1), RAEB (n=6), Refractory anemia with excess blasts in transformation (RAEB-t, n=2) and 
CMML (n=10). Dose limiting toxicities (DLT) of cumulative myelotoxicity and rash were 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 23 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
observed in 5 of 6 patients treated at 450 mg bid; therefore the maximally tolerated dose (MTD) 
was 400 mg bid for the first 21 days in each 28 day cycle. Distributed over all dose levels, 
objective responses (hematologic improvement, 3; partial remission, 2; or complete remission, 1) 
were seen in 6 of 20 (30%) evaluable patients, only 2 of whom had Ras mutations. Response 
sequences were unusual in some patients who had increases in platelet counts without 
intervening aplasia, while other responders demonstrated an initial, albeit modest, 
myelosuppressive effect (Kurzrock 2003).  
This was followed by a phase 2 study in which 28 patients (27 treatment assessable) were treated 
with 600 mg orally bid for 28 days, followed by 2 weeks rest. They were diagnosed with RA 
(n=5), RAEB (n=18) and RAEB-t (n=5). Three patients responded (complete remission, n = 2; 
partial remission, n = 1). Responders included 2 patients with RAEB and 1 patient with RAEB-t. 
Two of the responders had a diploid karyotype and one had multiple cytogenetic abnormalities 
including monosomy 5 and 7. The starting dose of 600 mg bid resulted in side effects 
(myelosuppression, fatigue, neurotoxicity, rash, or leg pain) necessitating dose reduction (n = 4) 
or discontinuation of therapy (n = 7) in 11 (41%) of 27 patients during the induction period (12 
weeks). Lower doses of 300 mg bid were well tolerated and all responses occurred in patients 
who had been reduced to 300 mg bid during the initial two cycles (Kurzrock 2004). 
A phase 2 study of tipifarnib was performed in intermediate to high risk MDS in which 82 
patients received tipifarnib 300 mg orally bid for the first 21 days of each 28 day cycle. Twenty-
six patients (32%) responded to tipifarnib: 12 (15%) complete responses and 14 (17%) 
hematologic improvements (HI); 37 patients (45%) had stable disease. Among the 12 complete 
responses, the median response duration was 11.5 months (range, 2.0-21.9 months), the median 
time to progression was 12.4 months (range, 3.9-23.8 months), and 7 were still alive at time of 
analysis (all > 3 years). Median overall survival was 11.7 months (95% CI, 9.4-15.0). Grade 3-4 
neutropenia (18%) and thrombocytopenia (32%) were the most common treatment-related AEs.  
Severe non-hematologic AEs were rarely reported. The authors concluded that tipifarnib was an 
active oral outpatient therapy that resulted in durable responses and hematologic improvement 
with TI. With few major infections or bleeding events reported, and only rarely non-hematologic 
toxicity, this treatment was very tolerable in patients with intermediate- to high-risk MDS 
(Fenaux 2007).  
Lastly, an alternate week dose regimen (bid days 1 – 7, and days 15 – 21 of a 28 day cycle) was 
evaluated in 63 MDS patients.  Sixteen of 61 (26%) evaluable patients responded (3 complete 
remissions and 13 hematologic improvements) with major platelet responses being most 
common (11 of 16 responders). There was no obvious dose-response relationship. Four of the 16 
responders (25%; including a complete responder) were treated at the lowest dose level (100 mg 
twice daily). Only one responder had a Ras mutation. Tipifarnib resulted in potent inhibition of 
FTase (usually more than 75%) in peripheral blood mononuclear cells regardless of dose and 
partial FTase inhibition persisted during the week off. The most common toxicity was 
myelosuppression (60% of patients). Twenty percent of patients had no side effects. Non-


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 24 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
hematologic toxicities included fatigue (20%), skin rash (9%), diarrhea (16%), increase in liver 
transaminases (14%) and bilirubin (11%), and nausea (11%). DLTs of ataxia (n = 1), fatigue (n = 
1), nausea (n = 1), and neutropenic fever (n = 2) occurred at tipifarnib doses above 1,200 mg/d. 
Alternate-week tipifarnib was concluded to be active and well tolerated at doses up to and 
including 600 mg orally twice daily (Kurzrock 2008). 
Additional details, including data on the use of tipifarnib in other hematological malignancies, as 
well as non-hematological malignancies, can be found in the Investigator’s Brochure. 
5.6 
Rationale for the Study 
The observations of objective complete response and partial response induced by single agent 
tipifarnib in heavily pretreated patients with MDS warrants further research. Its ease of 
administration and documented toxicity profile allow for outpatient treatment.  Furthermore, 
given the high unmet medical need and lack of therapeutic options for patients who have failed 
prior therapy for MDS, tipifarnib may provide a critical new therapeutic option in the 
armamentarium for MDS therapy.  
Moreover, there are molecular biological arguments for the use of tipifarnib, such as the role of 
interference with the Ras signalling pathway which is frequently activated in MDS.   In addition, 
it has been proposed that tipifarnib may suppress abnormal NK cell function and autoimmunity 
that contributes to MDS (Sugimori 2010, Epling-Burnette 2008).   Tipifarnib may have particular 
value in low or intermediate risk MDS patients where autoimmunity is known to play a role and 
immunosuppression is an active but not optimal form of treatment. The potential for tipifarnib to 
suppress NK cell-mediated auto-immunity and restore normal immune surveillance may translate 
to therapeutic benefit in this population.   
Two dosing regimens will be tested based on the prior experience with tipifarnib in patients with 
MDS (see Section 9.4), each employing a Simon two stage design. This design was selected in 
order to minimize the number of study subjects treated if tipifarnib were considered not 
sufficiently efficacious to grant further development in this subject population.  As part of 
Amendment 3, eligibility criteria have been modified to include subjects with baseline 
neutrophils < 1000/mm3 and platelets > 20,000/mm3 based on the review by the Sponsor of data 
from a prior trial of tipifarnib in subjects with intermediate and high risk MDS (Fenaux 2007). In 
brief, in study INT-28, subjects with peripheral neutrophil counts >1000/mm3 and platelet 
counts < 20,000/mm3 appeared less likely to receive clinical benefit from tipifarnib therapy. 
These results may reflect the known effects on neutrophil bone marrow homing (J Innate Immun 
2013; 5:304-314) and platelet production (Blood 2012; 120:2775-6. 24) of the CXCL12/CXCR4 
pathway, recently identified as a target of tipifarnib (http://www.kuraoncology.com/wp-
content/uploads/2017/06/KO-TIP-002-EHA-2017-Poster-v2017-06-01-FINAL.pdf). A 
relationship between CXCL12/CXCR4 expression, hematology parameters and outcome of 
tipifarnib therapy will be investigated as an exploratory aim of the present study. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 25 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Thus the assessment of the effect of tipifarnib in MDS is warranted. 
The rationale for the selection of the dose and treatment regimen is provided in Section 9.4. 
6 
OBJECTIVES 
6.1 
Primary Objectives and Endpoints 
Primary Objective: To assess the antitumor activity of tipifarnib in terms of ORR in subjects 
with risk MDS. 
Primary endpoint: Response assessments according to the MDS IWG criteria (Table 9 and 
Table 10) 
6.2 
Secondary Objectives and Endpoints 
Secondary Objective 1: To assess the effect of tipifarnib on the following: 
• Rate of Transfusion Independence 
• Duration of Transfusion Independence 
• Hematologic Improvement 
• Duration of Response 
• Rate of PFS at 1 year 
• Rate of survival at 1 year 
• Safety and tolerability 
Secondary Endpoint 1: Response assessments according to the MDS IWG criteria (Table 9 and 
Table 10); Transfusion requirements and hemoglobin levels during the study period; AE and 
SAE evaluated according to NCI CTCAE v.4.03.   
Secondary Objective 2: To evaluate the activity of tipifarnib in subjects treated with two 
different tipifarnib dose regimens (regimen 1 and regimen 2). 
Secondary Endpoint 2: Response assessments according to the MDS IWG criteria (Table 9 and 
Table 10)   
 
 
 
 
  
 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 26 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
 
 
 
 
  
 
 
 
 
7 
SUBJECT SELECTION 
7.1 
Inclusion Criteria 
For inclusion of a subject in the study, all of the following inclusion criteria must be fulfilled: 
1. Subject is at least 18 years of age. 
2. Documented pathological evidence of MDS as defined by the WHO criteria (Table 8). 
3. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2. 
4. Subjects have no known curative treatment.    
5. Subject is willing and able to comply with scheduled visits, treatment plans, laboratory tests 
and other procedures (including bone marrow assessments). 
6. At least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1.  Subjects 
must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities (excluding 
Grade 2 toxicities that are not considered a safety risk by the Sponsor and Investigator) or 
toxicity must be deemed irreversible by the Investigator. 
7. Acceptable hematological function: 
a. Absolute neutrophil count < 1000/mm3 
b. Platelet count > 20,000/mm3 
8. Acceptable liver function:  
a. Total or direct bilirubin ≤ 1.5 x ULN; does not apply to subjects with Gilbert’s syndrome 
diagnosed as per institutional guidelines. 
b. AST (SGOT) and ALT (SGPT) ≤ 2.5 x ULN. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 27 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
9. Acceptable renal function with serum creatinine ≤ 1.5 x ULN or a calculated creatinine 
clearance ≥ 60 mL/min using the Cockcroft-Gault or Modification of Diet in Renal Disease 
formulas. 
10. Female subjects must be: 
a. Of non-child-bearing potential (surgically sterilized or at least 2 years post-menopausal); 
or 
b. If of child-bearing potential, subject must use a highly effective method of contraception, 
such as combined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation, progestogen-only hormonal contraception 
associated with inhibition of ovulation, intrauterine device,  intrauterine hormone-
releasing system, bilateral tubal occlusion, vasectomised partner or sexual abstinence.  
Both females and male subjects with female partners of child-bearing potential must 
agree to use a highly effective method of contraception for 2 weeks prior to screening, 
during, and at least 4 weeks after last dose of trial medication. Female subjects must have 
a negative serum or urine pregnancy test within 72 hours prior to start of trial medication. 
c. Not breast feeding at any time during the study. 
11. Written and voluntary informed consent understood, signed and dated. 
7.2 
Exclusion Criteria 
1. Known prior progression to AML, defined by at least 20% blasts in the blood or bone 
marrow. 
2. Myelodysplastic or myeloproliferative syndrome other than MDS. 
3. More than two prior systemic regimens for MDS.  Prior systemic regimens are those that are 
considered standard of care for the treatment of MDS, have been received at standard doses 
for at least one full treatment cycle and exclude ESA.   
4. Prior cytoreductive therapy for blast reduction. 
5. Participation in any interventional study within 1 week or 5 half lives (whichever is longer) 
of Cycle 1 Day 1. 
6. Ongoing treatment with an anticancer agent for MDS not contemplated in this protocol. 
7. Prior treatment (at least 1 full treatment cycle) with a farnesyltransferase inhibitor. 
8. Clinically significant anemia due to iron, B12, or folate deficiencies, or autoimmune or 
hereditary hemolytic anemia, or gastrointestinal bleeding. If marrow stain for iron is not 
available, the transferrin saturation (iron/total iron binding capacity Fe/TIBC) must be >20% 
or serum ferritin must be >100 ng/dL. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 28 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
9. Active coronary artery disease requiring treatment, myocardial infarction within the prior 
year, New York Heart Association grade III or greater congestive heart failure, cerebro-
vascular attack within the prior year, or current serious cardiac arrhythmia requiring 
medication except atrial fibrillation. 
10. Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without 
complete recovery. 
11. Active, concurrent malignancy requiring radiation, chemotherapy, or immunotherapy 
(excluding non-melanoma skin cancer, adjuvant hormonal therapy for breast cancer and 
hormonal treatment for castration sensitive prostate cancer).  
12. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. Known 
infection with human immunodeficiency virus (HIV), or an active infection with hepatitis B 
or hepatitis C. 
13. Subjects who have exhibited allergic reactions to tipifarnib, or structural compounds similar 
to tipifarnib or to its excipients. 
14. Concomitant disease or condition that could interfere with the conduct of the study, or that 
would, in the opinion of the investigator, pose an unacceptable risk to the subject in this 
study.  
15. The subject has legal incapacity or limited legal capacity. 
16. Significantly altered mental status that would limit the understanding or rendering of 
informed consent and compliance with the requirements of this protocol. Unwillingness or 
inability to comply with the study protocol for any reason. 
8 
TRIAL DESIGN 
8.1 
Study Design 
This phase 2 study will investigate the antitumor activity in terms of ORR of tipifarnib in 
approximately 36 eligible subjects with MDS who have no known curative treatment.   
A two-stage study design was selected in order to minimize the number of study subjects treated 
if tipifarnib were considered not sufficiently efficacious to grant further development in this 
subject population. This design is intended to allow the termination of accrual in case of 
unacceptably low efficacy as measured by ORR.   
In the first stage, 22 eligible subjects will be enrolled and randomized in to one of two dose 
regimen cohorts (11 subjects per cohort). If two or more responses are observed in a given dose 
regimen cohort, 7 additional study subjects will be enrolled.  Each dose regimen cohort is 
designed to test the null hypothesis of ORR rate less than 10% vs alternative hypothesis of ORR 
rate at least 30% and will be evaluated independently.  At the completion of the study, treatment 
will be considered of further interest if the true ORR rate is higher than 10% (at least 4 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 29 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
responders out of 18 subjects in a dose regimen cohort). This design provides 80% power to 
detect a difference between 10% and 30% ORR rate at one-sided significance level of 0.087. 
Only consented subjects who meet all eligibility criteria will be enrolled in the study. Screening 
evaluations will be completed within 4 weeks (28 days) of Cycle 1 Day 1. Any screening 
evaluation, including disease status, will need to be repeated if performed more than 4 weeks 
from Cycle 1 Day 1. Evaluations performed as part of the standard of care within 28 days of 
dosing but prior to consent, do not need to be repeated. By signing the consent form, study 
subjects agree to the collection of standard of care health information.     
Subjects will be randomized to receive tipifarnib orally with food, twice a day (bid) according to 
one of the following dose regimens: 
• Regimen 1: 600 mg bid for 7 days on Days 1-7 in 28 day cycles (i.e. 1 week on / 3 weeks 
off).  
At the discretion of the investigator, the dose of tipifarnib may be increased to 800 mg bid if 
the subject has not experienced dose limiting toxicities at the 600 mg dose level. Subjects are 
not to be dose escalated until after completing Cycle 1 to ensure the dosing regimen is 
tolerated prior to escalation.  Subjects who develop serious adverse events, ≥ grade 2 TEAEs 
that are deemed related to tipifarnib and lasting ≥ 14 days will not undergo dose 
escalation.  Stepwise 200 mg dose reductions to control treatment-related, treatment-
emergent toxicities are also allowed. Subjects who develop serious adverse events (SAE), ≥ 
grade 2 treatment-emergent adverse events (TEAE) that are deemed related to tipifarnib and 
lasting ≥ 14 days will not undergo dose escalation.   
• Regimen 2: 300 mg bid for 21 days on Days 1-21 in 28 day cycles (i.e. 3 weeks on / 1 
week off).  
Stepwise 100 mg dose reductions to control treatment-related, treatment-emergent toxicities 
are allowed. 
Subjects who received a starting dose of 900 mg bid during the conduct of the original version of 
this protocol may be dose reduced to the 600 mg bid dose at the discretion of the investigator.  
Subjects who received tipifarnib on Days 1 – 7 and Days 15 – 21 during the conduct of the 
original version and amendment 1 of this protocol, may transition to the new treatment 
administration schedule (tipifarnib on Days 1-7 in 28 day cycles) beginning on Day 1 of their 
next cycle. 
Subjects may use proton pump inhibitors or H2 antagonists during the treatment portion of this 
study. However, subjects should be instructed to use antacids (magnesium or aluminum 
containing products) at least 2 hours before or after intake of oral study drug. 
In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment 
until disease progression.  If a complete remission is observed, therapy with tipifarnib will be 
maintained for at least 6 months beyond the start of response.  


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 30 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Hematologic assessments, including peripheral blood evaluations and review of transfusion 
requirements, will be performed at screening and at least monthly until disease progression.  
Disease assessments will also be performed at screening and at least once every approximately 
12 weeks starting at the end of cycle 3.  As part of the disease assessment at screening and during 
Cycles 3, 6 and 9, bone marrow evaluation will be performed.  Thereafter, bone marrow 
evaluations will occur during disease assessments in accordance with institutional standard 
practice.  Additional hematologic or disease assessments may be conducted if deemed necessary 
by the Investigator. The timing of the hematologic and disease assessments should be maintained 
as much as possible independently of potential treatment cycle delays. 
Determination of ORR will be assessed by the Investigator according to the MDS IWG criteria 
(Table 9 and Table 10).   
Upon disease progression, all subjects in the study cohort will be followed approximately every 
12 weeks for survival and the use of subsequent therapy until either death or 12 months after 
accrual of the study cohort has been completed, whichever occurs first. Information on survival 
and subsequent anticancer therapy may be collected by phone. 
Subjects who terminate treatment for reasons other than death or disease progression will be 
assessed at regular intervals for disease progression (approximately every 12 weeks) and 
leukemic transformation (monthly blood counts).  Disease assessments performed during the first 
9 months from the start of the subject’s participation in the study will include bone marrow 
evaluation.  Thereafter, bone marrow evaluations will occur during disease assessments in 
accordance with institutional standard practice.  These assessments will continue until disease 
progression, withdrawal of subject’s consent to study procedures or initiation of another 
anticancer therapy.   
All subjects will be followed-up for safety during treatment and up to approximately 30 days (30 
± 7 days) after treatment discontinuation or until immediately before the initiation of another 
anticancer therapy, whichever occurs first. Additional follow up may be implemented until the 
subject recovers from any emergent treatment related toxicity or the adverse event is considered 
irreversible by the Investigator. Target organ toxicities will be monitored via clinical and 
laboratory assessments using the NCI CTCAE v.4.03 criteria. 
8.2 
Subject Identification and Replacement of Subjects 
Each subject will be assigned a unique subject identifier. This unique identifier will be on all 
case report form (CRF) pages. Subjects who do not receive at least one dose of tipifarnib will be 
replaced.  
8.3 
Assignment to Treatment Groups 
All eligible subjects will be randomized to receive tipifarnib administered according to one of the 
following dose regimens: 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 31 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
• Regimen 1: 600 mg bid for 7 days on Days 1-7 in 28 day cycles (i.e. 1 week on / 3 weeks 
off).  
• Regimen 2: 300 mg bid for 21 days on Days 1-21 in 28 day cycles (i.e. 3 weeks on / 1 
week off).  
8.4 
Removal of Subjects from Treatment or Assessment 
Subjects may withdraw their consent to participate in this study at any time without prejudice. 
The Investigator must withdraw from the study any subject who requests to be withdrawn. A 
subject’s participation in the study may also be discontinued at any time at the discretion of the 
Investigator and in accordance with his/her clinical judgment. Every effort should be made to 
complete, whenever possible, the tests and evaluations listed for the End of Treatment visit. The 
Sponsor must be notified of all subject withdrawals as soon as possible. The Sponsor also 
reserves the right to discontinue the study at any time for either clinical research or 
administrative reasons and to discontinue participation by an individual Investigator or site for 
poor enrollment or noncompliance. 
Overall, the reasons for which the Investigator or Kura Oncology may withdraw a subject from 
study treatment include, but are not limited to, the following: 
• Subject experiences disease progression 
• Subject experiences unacceptable toxicity 
• Subject requires more than 2 dose reductions 
• Subject experiences toxicity that is deemed by the Investigator to be no longer safe for 
the subject to continue therapy 
• Subject requests to withdraw from the study treatment 
• Subject requires or has taken medication prohibited by the protocol 
• Subject is unwilling or unable to comply with the study requirements 
• Subject withdraws consent to collect health information 
• Subject was erroneously admitted into the study or does not meet entry criteria 
• Subject is lost to follow-up 
• Subject becomes pregnant 
Subjects will return for an End of Treatment visit within approximately 30 days after the last 
administration of the study drug (or sooner if another anticancer therapy is to be initiated). If a 
subject fails to return for scheduled visits, a documented effort must be made to determine the 
reason. If the subject cannot be reached by telephone after 2 attempts, a certified letter should be 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 32 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
sent to the subject (or the subject’s legally authorized representative, if appropriate) requesting 
contact with the Investigator. This information should be recorded in the study records.  
Prior to enrollment into the study, the Investigator or designee must explain to each subject, that 
the subject’s protected health information obtained during the study may be shared with the 
study Sponsor, regulatory agencies, and Institutional Review Board/Independent Ethics 
Committee (IRB/IEC) in order to analyze and evaluate study results. It is the Investigator’s (or 
designee’s) responsibility to obtain written permission to use protected health information per 
country-specific regulations, such as Health Information Portability and Accountability Act 
(HIPAA) in the United States, from each subject, or if appropriate, the subject’s legally 
authorized representative. If permission to use protected health information is withdrawn, it is 
the Investigator’s responsibility to obtain a written request, to ensure that no further data will be 
collected from the subject and the subject will be removed from the study. 
8.5 
Premature Discontinuation of the Trial 
This study may be discontinued prematurely in the event of any of the following: 
• New information leading to a judgment of unfavorable risk-benefit of tipifarnib becomes 
available, e.g. evidence of inefficacy of tipifarnib in subjects with very low, low or INT 
risk MDS, occurrence of significant previously unknown adverse reactions or 
unexpectedly high intensity or incidence of previously known adverse reactions, or other 
unfavorable safety findings in the very low, low or INT risk MDS patient population. 
Evidence of inefficacy may arise from this study or from other trials; unfavorable safety 
findings may arise from clinical or non-clinical examinations, e.g. toxicology. 
• Sponsor’s decision that continuation of the study is unjustifiable for medical or ethical 
reasons. 
• Poor enrollment of subjects making completion of the study within an acceptable time 
frame unlikely.  
• Discontinuation of development of tipifarnib by the Sponsor.  
• Request by a Health Authority. 
Health Authorities and IRBs/IECs will be informed about the discontinuation of the study in 
accordance with applicable regulations. In the case of premature discontinuation of the study, the 
investigations scheduled for the End of Treatment assessment should be performed and the 
appropriate CRF section completed. 
8.6 
Definition of End of Study 
For administrative and safety reporting purposes, the end of this clinical study is defined as 12 
months from enrollment of the last enrolled study subject.  If the last enrolled study subject 
discontinues treatment within 12 months of study enrollment, the End of Study will occur no 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 33 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
earlier than the date of the last enrolled subject’s safety follow-up assessment performed 
approximately 30 days after treatment discontinuation (or until initiation of another anti-cancer 
therapy).  At the time of End of Study, provisions will be made to transition all remaining study 
subjects who demonstrate sustained clinical benefit beyond the end of the study to other means 
of continued treatment with appropriate safety monitoring, e.g. single patient treatment protocol. 
9 
TREATMENTS 
Subjects will receive tipifarnib as monotherapy in this study. In the absence of unmanageable 
toxicities, subjects may continue to receive tipifarnib treatment until disease progression.  If a 
complete remission is observed, therapy with tipifarnib will be maintained for at least 6 months 
beyond the start of response.  
Kura Oncology, Inc. or its designee will provide the study site with a supply of tipifarnib 
sufficient for the completion of the study. 
All study subjects will be also eligible to receive best supportive care (BSC) defined as any 
standard supportive measures that are not considered a primary treatment of the disease under 
study. BSC will be provided by the study sites. 
9.1 
Investigational Product 
Tipifarnib is a small molecule being developed as a potent, selective inhibitor of FTase for the 
treatment of cancer and other malignancies. 
9.1.1 
Product Characteristics 
Tipifarnib film-coated tablets for oral administration are supplied in HDPE bottles. Two 
strengths (100 mg and 300 mg) of tablets are provided containing either 100 or 300 mg of 
Tipifarnib active substance, respectively. In addition to the active substance, the tablets contain 
the following inactive ingredients: lactose monohydrate, maize starch, hypromellose, 
microcrystalline cellulose, crospovidone, colloidal anhydrous silica, and magnesium stearate. 
The nonfunctional, taste-masking film coatings contain hypromellose, titanium dioxide, lactose 
monohydrate, polyethylene glycol, and triacetin. Each strength of tablet has the same excipients 
but the quantitative composition is slightly different. Further information can be obtained from 
the current version of the Investigator’s Brochure.  
9.1.2 
Storage and Labeling 
At a minimum, the label of each bottle of tipifarnib tablets shipped to the study sites will provide 
the following information: batch number/lot number, study identification, required storage 
conditions, directions for use, and country specific required caution statements (including “New 
Drug – Limited by United States federal law to investigational use” language). 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 34 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Tipifarnib accountability records will be maintained by the pharmacy or designated drug 
preparation area at the study sites. Upon receipt of tipifarnib supplies, the pharmacist or 
designated study site investigational drug handler will inventory tipifarnib (separately for each 
strength, if applicable) and complete the designated section of the shipping form. The 
shipping/inventory form must be sent to Kura Oncology, Inc. or its designee, as instructed. 
Tipifarnib should be stored at controlled room temperature 15 to 30 C (59 to 86 F). All study 
supplies must be kept in a restricted access area. 
9.2 
Treatment Administration 
Tipifarnib will be administered orally, with food to each subject according to one of the 
following dose regimens: 
• Regimen 1: 600 mg bid for 7 days on Days 1-7 in 28 day cycles (i.e. 1 week on / 3 weeks 
off).  
• Regimen 2: 300 mg bid for 21 days on Days 1-21 in 28 day cycles (i.e. 3 weeks on / 1 
week off).  
On Day 1 of Cycle 1, only 1 dose of tipifarnib will be administered and will take place in the 
evening.  Thereafter, tipifarnib will be administered orally with a meal in the mornings and again 
approximately 12 hours later, at approximately the same times each treatment day. Tablets 
should be swallowed whole with water (~8 oz. or 250 mL), but may be chewed or crushed if the 
Investigator deems it necessary.   
Subjects may use proton pump inhibitors or H2 antagonists during the treatment portion of this 
study. However, subjects should be instructed to use antacids (magnesium or aluminum 
containing products) at least 2 hours before or after intake of oral study drug. 
On Cycle 1 Day 1, the study site will provide tipifarnib to the subject from bulk supplies.  
Subjects will be provided with diaries with instructions to record the date and time of each dose 
and asked to bring the diaries and tablet bottles to each clinic visit for subject compliance and 
drug accountability review by the site staff.   
9.3 
Treatment Assignment 
Treatment will be conducted in an open label manner and subjects will be randomized to one of 
the dose regimens to be evaluated in this study (as outlined in Section 9.2).  Kura Oncology, Inc 
or its designee will assign a subject number identifier for each subject that is enrolled into the 
study. Study sites cannot enroll or start dosing the subject without receiving the assigned subject 
number.   


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 35 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
9.4 
Dose Selection 
This study will evaluate two dose regimens: 600 mg administered bid on Days 1 – 7 of 28 day 
treatment cycles with the possibility to dose escalate to 800 mg bid, or to dose reduce to 400 or 
200 mg bid, and 300 mg administered bid on Days 1 – 21 of 28 day treatment cycles with the 
possibility to dose reduce to 200 or 100 mg bid in order to support optimal dose selection for 
further clinical studies in subjects with MDS who are RBC transfusion dependent.   
In the majority of its phase 2 program, tipifarnib was given orally at a dose of 300 mg bid for 21 
days, followed by 1 week of rest, in 28 day treatment cycles (3 weeks on/1 week off schedule).  
Prior studies have shown that 
 
 those shown to demonstrate anti-tumor activity in preclinical tumor models.  In a 
multicenter, phase 2 study in higher risk MDS patients (INT-28, N = 82), in which tipifarnib 300 
mg bid was administered on the 3 weeks on/1 week off schedule, the response rate (CR + CRp + 
PR) was 15.9% and did not meet prespecified criteria (30% in order to reject null hypothesis) to 
support continued development in MDS using 300 mg bid 3 weeks on/1 week off.   The most 
frequently reported hematologic AEs were thrombocytopenia (41%), anemia (34%), and 
granulocytopenia (29%).  The most frequently reported non-hematologic AEs were fatigue 
(51%), diarrhea (38%), nausea (37%), and rash (24%). The observed safety profile in MDS 
patients was broadly similar to the other patient populations in which tipifarnib has been tested.  
For further details, please refer to the Investigator’s Brochure. 
However, given the underlying cytopenias often observed in patients with MDS, consideration 
was made for exploring alternative regimens that have been associated with less 
myelosuppression.  The effect of higher dose levels given at intermittent schedules was tested in 
several clinical studies, including two trials in MDS and AML patients investigating alternate 
week dosing (7-day bid dosing followed by 7-day rest).  
An alternate week dose regimen (bid days 1 – 7, and days 15 – 21 of a 28 day cycle) was 
investigated in 63 MDS patients.  Sixteen of 61 (26%) evaluable patients responded (3 complete 
remissions and 13 hematologic improvements) with major platelet responses being most 
common (11 of 16 responders). The most common toxicity was myelosuppression (60% of 
patients). Twenty percent of patients had no side effects. Non-hematologic toxicities included 
fatigue (20%), skin rash (9%), diarrhea (16%), increase in liver transaminases (14%) and 
bilirubin (11%), and nausea (11%). DLTs of ataxia (n = 1), fatigue (n = 1), nausea (n = 1), and 
neutropenic fever (n = 2) occurred at tipifarnib doses above 1,200 mg/d. Alternate-week 
tipifarnib was concluded to be active and well tolerated at doses up to and including 600 mg 
orally twice daily (Kurzrock 2008).   
Additionally, the alternate week schedule was evaluated in patients with relapsed/refractory 
AML at doses up to 1600 mg bid. At the 400 mg bid dose level, a grade 5 hepatorenal failure 
occurred, potentially related to the study drug. There were no additional DLTs reported at 600, 
800 or 1000 mg bid dose levels. At the 1200 mg bid dose level, a grade 3 creatinine elevation 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 36 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
was seen in one patient out of 6 treated. At the 1400 mg bid dose level, one patient experienced a 
grade 4 hypotension and a rising grade 2 creatinine that were dose limiting, and a second patient 
had a rising grade 2 creatinine that resulted in treatment discontinuation and was therefore 
considered dose limiting. At the 1600 mg dose level, grade 3 liver function tests and a rising 
grade 2 creatinine were dose limiting, and in a second patient, a rapidly rising creatinine was 
seen and treatment stopped. As a result, the 1200 mg bid dose was established as the MTD and 7 
additional patients treated. Sixteen patients were treated at the 1000 and 1200 mg dosing levels, 
with 3 of them experiencing complete responses. No formal responses were seen among patients 
treated at the lower dose levels (Kirschbaum 2011). 
Based on these data, 
 for evaluation in this 
study.  However, 
 
 in 
amendment 1.  Additionally, intra-patient dose escalation to 800 mg bid is allowed at the 
discretion of the investigator if the subject has not experienced dose limiting toxicities at the 600 
mg dose level.  Subjects are not to be dose escalated until after completing Cycle 1 to ensure the 
dosing regimen is tolerated prior to escalation. 
Upon review of the first 9 subjects enrolled in the study, the investigators noted that the 
alternative week regimen may not provide sufficient recovery time in subjects who experience 
myelosuppressive effects of tipifarnib.  Therefore, the protocol was amended (Amendment 2) to 
adjust the treatment administration schedule to bid on Days 1 – 7 of 28 day treatment cycles.  
The investigators considered that by adjusting the dose regimen to allow for a 3 week rest period 
following each week of dosing, the myelosuppressive effects will be mitigated allowing subjects 
to make gains on increasing the cell counts as the cycles progress.  Additionally, given the prior 
experience and tolerability with 300 mg bid on Days 1 – 21 of 28 day treatment cycles, this 
regimen was incorporated into Amendment 2 to support dose selection in future clinical studies.  
Both dose regimens are expected to be well tolerated and to potentially provide clinical benefit to 
subjects with MDS.  Furthermore, the current study allows for step-wise 100 - 200 mg dose 
adjustment based on subject tolerability.  The data obtained from this study will be used to select 
the optimal dose and dose regimen to support the further development of tipifarnib in subjects 
with MDS.   
 
 
 
 
 
 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 37 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
 
 
 
 
 
 
   
 
  








Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 41 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
 
 
 
 
9.6 
Treatment of Overdose 
An overdose is defined as any dose greater than 30% over the daily tipifarnib dose. Any 
overdose must be recorded in the study medication and adverse event sections of the CRF. There 
is no known antidote for tipifarnib. In the event of overdose of tipifarnib, subjects should receive 
appropriate advice and supportive medical care by the Investigator or his/her designee and be 
followed-up accordingly. 
For monitoring purposes, any case of overdose – whether or not associated with an AE (serious 
or non-serious) – must be reported to the Sponsor in an expedited manner. 
9.7 
Blinding 
This is an open label study with no placebo or comparators. 
9.8 
Treatment Compliance 
The importance of treatment compliance should be emphasized to the subject. Subjects will be 
given study drug and detailed instructions on how to take medications at home. Subjects will be 
instructed to return all used and unused study drug containers at each study visit. Subject 
compliance with the dosing schedule will be assessed by reconciliation of the used and unused 
study drug at each clinic visit and review of the dosing diaries. The quantity dispensed, returned, 
used, lost, etc. must be recorded on the dispensing log provided.  
Compliance will be monitored and documented by site personnel on the appropriate form. The 
site personnel will question the subject regarding adherence to the dosing schedule by reviewing 
the dosing diaries, recording the number of tablets (and strengths, if applicable) returned, the 
date returned, and determining treatment compliance (at least 80% of the total assigned dose) 
before dispensing new medication to the study subject. 
9.9 
Investigational Product Accountability 
The Investigator or designee is responsible for maintaining accurate records (including dates and 
quantities) of receipt of investigational product (IP), subjects to whom IP is dispensed (subject 
by subject specific accounting), and loss or accidental or deliberate destruction of IP.  


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 42 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
9.10 
Return and Disposition of Clinical Supplies 
Unused tablets returned by the subject from a prior cycle of treatment may be re-dispensed to the 
subject. Study drug must be kept in a secure location for accountability and reconciliation by the 
Sponsor’s designated clinical study monitor. The Investigator or designee must provide an 
explanation for any destroyed or missing study drug or study materials. 
Study drug may be destroyed on site, per the site’s standard operating procedures, but only after 
the Sponsor or its designee has been notified and granted approval for drug destruction. All study 
drug destroyed on site must be documented. 
Documentation must be provided to the Sponsor or its designee and retained in the Investigator’s 
study files. If a site is unable to destroy study drug appropriately, the site can return unused study 
drug to the Sponsor or its designee upon request. The return of study drug or study drug 
materials must be accounted for on a form provided by the Sponsor or its designee. 
All study drug and related materials should be stored, inventoried, reconciled, and destroyed or 
returned according to applicable state and federal regulations and study procedures. 
9.11 
Prior and Concomitant Medications 
All prescription and over-the-counter medications taken by a subject within 28 days before the 
first study drug administration will be recorded in the CRF.  In particular, subjects will be asked 
about the use of agents that may affect the mevalonate pathway including statins (e.g. 
atorvastatin, simvastatin, rosuvastatin, pravastatin), bisphosphonates (e.g. pamidronate, 
risedronate, ibandronate, etidronate, alendronate) and nutritional agents (e.g. coenzyme Q₁₀, 
ubiquinone). Any additional concomitant therapy that becomes necessary during the study and 
any change to concomitant drugs must be recorded in the corresponding section of the CRF, 
noting the name, dose, duration and indication of each drug. 
Supportive care medications considered necessary for the subject’s safety and well-being may be 
given at the discretion of the Investigator according to local guidelines and standard practices. 
For concomitant therapy given as a treatment for a new condition or a worsening of an existing 
condition, the condition must be reported on the AE form of the CRF. 
Subjects may use proton pump inhibitors or H2 antagonists during the treatment portion of this 
study. However, subjects should be instructed to use antacids (magnesium or aluminum 
containing products) at least 2 hours before or after intake of oral study drug. 
Corticosteroids (up to 10 mg prednisone daily or its equivalent) may be administered for 
concomitant medical conditions. 
Any additional concomitant therapy that becomes necessary during the study and any change to 
concomitant drugs must be recorded in the corresponding section of the CRF, noting the name, 
dose, duration and indication of each drug. 






Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 45 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Disease response assessment will be performed by the Investigator according to the MDS IWG 
criteria (Table 9 and Table 10).   
Determination of RBC TI (secondary endpoint) will be assessed by the investigator through the 
review of subject transfusion requirements and hemoglobin levels.  RBC TI will be defined as 
the absence of the intravenous infusion of any RBC transfusion during any consecutive “rolling” 
56 days during the treatment period, i.e. days  1 to 56, days 2 to 57, days 3 to 58, etc. and a ≥ 1 
g/dL increase in hemoglobin level.   
Upon disease progression, all subjects in the study cohort will be followed approximately every 
12 weeks for survival and the use of subsequent therapy until either death or 12 months after 
accrual of the study cohort has been completed, whichever occurs first. Information on survival 
and subsequent anticancer therapy may be collected by phone. 
Subjects who terminate treatment for reasons other than death or disease progression will be 
assessed at regular intervals for disease progression (approximately every 12 weeks) and 
leukemic transformation (monthly blood counts).  Disease assessments performed during the first 
9 months from the start of the subject’s participation in the study will include bone marrow 
evaluation.  Thereafter, bone marrow evaluations will occur during disease assessments in 
accordance with institutional standard practice.  These assessments will continue until disease 
progression, withdrawal of subject’s consent to study procedures or initiation of another 
anticancer therapy.   
10.2 
Assessment of Safety 
AEs will be graded according to the NCI CTCAE v4.03. AEs will be summarized by relationship 
to study drug, severity and grade. The safety profile of tipifarnib will be assessed through the 
recording, reporting and analyzing of baseline medical conditions, adverse events, physical 
examination findings including vital signs and laboratory tests. Comprehensive assessment of 
any apparent toxicity experienced by the subject will be performed throughout the course of the 
study, from the time of the subject’s signature of informed consent. Study site personnel will 
report any AE, whether observed by the Investigator or reported by the subject. 
A safety monitoring committee comprised of the Investigator(s) and Sponsor clinicians or 
designees will review all relevant safety data on a regular basis. 
10.3 
Adverse Events 
An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product, which does not necessarily have a causal relationship 
with this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal product, whether or not considered related to the medicinal product. In cases of 
surgical or diagnostic procedures, the condition/illness leading to such a procedure is considered 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 46 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
as the AE rather than the procedure itself. In case of a fatality, the cause of death is considered as 
the AE, and the death is considered as its outcome. 
The Investigator is required to grade the severity/intensity of each adverse event. Investigators 
will reference the NCI-CTCAE v 4.03. This is a descriptive terminology that can be used for 
adverse event reporting. A general grading (severity/intensity) scale is provided at the beginning 
of the referenced document, and specific event grades are also provided. If a particular AE’s 
severity/intensity is not specifically graded by the guidance document, the Investigator is to 
revert to the general definitions of Grade 1 through Grade 5 and use his or her best medical 
judgment. 
The 5 general grades are: 
• Grade 1: Mild 
• Grade 2: Moderate 
• Grade 3: Severe 
• Grade 4: Life-threatening or disabling 
• Grade 5: Death related to AE. Note: Death (Grade 5 as defined by NCI-CTCAE version 
4.03) is mainly regarded as an outcome, to be documented as described below. 
According to the Sponsor’s convention, if a severity/intensity of Grade 4 or 5 is applied to an 
AE, then the Investigator must also report the event as a SAE as per Section 10.5. However, a 
laboratory abnormality with a severity/intensity of Grade 4, such as anemia or neutropenia, is 
considered serious only if the condition meets one of the serious criteria described below. 
In the case of death, the primary cause of death (the event leading to death) should be recorded 
and reported as an SAE. “Fatal” will be recorded as the outcome of this respective event; death 
will not be recorded as separate event. Only if no cause of death can be reported (e.g., sudden 
death, unexplained death), the death per se might be reported as an SAE. 
Investigators must also systematically assess the causal relationship of AEs to the IPs, other 
medicinal products using the following definitions. Decisive factors for the assessment of causal 
relationship of an AE to the study treatments include, but may not be limited to, temporal 
relationship between the AE and the study treatments, known side effects of the study treatments, 
medical history, concomitant medications and procedures, course of the underlying disease, 
study procedures. 
Relatedness of an AE will be evaluated as follows: 
• Not related: Not suspected to be reasonably related to the IPs. AE could not medically 
(pharmacologically/clinically) be attributed to the IPs under study in this clinical study 
protocol. A reasonable alternative explanation must be available. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 47 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
• Related: Suspected to be reasonably related to the IPs. AE could medically 
(pharmacologically/clinically) be attributed to the IPs under study in this clinical study 
protocol. 
10.4 
Abnormal Laboratory Findings and Other Abnormal 
Investigational Findings 
Abnormal laboratory findings and other abnormal investigational findings (e.g. on an ECG trace) 
should not be reported as AEs unless they are associated with clinical signs and symptoms, lead 
to treatment discontinuation or are considered otherwise medically important by the Investigator. 
If an abnormality fulfills these criteria, the identified medical condition, e.g. anemia, increased 
alanine aminotransferase (ALT), must be reported as the AE rather than the abnormal value 
itself. 
10.5 
Serious Adverse Event 
An SAE is any untoward medical occurrence that at any dose: 
• Results in death. 
• Is life-threatening. NOTE: The term “life-threatening” in this definition refers to an event 
in which the subject is at risk of death at the time of the event; it does not refer to an 
event that hypothetically might cause death if it were more severe. 
• Requires inpatient hospitalization or prolongation of existing hospitalization. 
• Results in persistent or significant disability/incapacity. 
• Is a congenital anomaly/birth defect. 
• Is otherwise considered as medically important. 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered as SAEs when, based upon appropriate medical judgment, 
they may jeopardize the subject or may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. Examples of such events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions 
that do not result in subject hospitalization, or the development of drug dependency or drug 
abuse. 
For the purposes of reporting, any suspected transmission of an infectious agent via an IP is also 
considered a serious adverse reaction and all such cases should be reported in an expedited 
manner. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 48 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
10.6 
Events that Do Not Meet the Definition of an SAE 
Elective hospitalizations to administer, or to simplify study treatment or study procedures (e.g. 
an overnight stay to facilitate chemotherapy and related hydration therapy application) are not 
considered as SAEs. However, all events leading to unplanned hospitalizations or unplanned 
prolongation of an elective hospitalization (e.g., undesirable effects of any administered 
treatment) must be documented and reported as SAEs. 
10.7 
Events Not to Be Considered as AEs/SAEs 
Medical conditions that are present at the initial study visit that do not worsen in severity or 
frequency during the study are defined as Baseline Medical Conditions and are NOT to be 
considered AEs. Progression of underlying disease is not an AE and therefore not an SAE per se, 
rather an efficacy end-point, unless deemed to be causally related to administration of IPs. 
However, if adverse signs or symptoms occur in association with disease progression then these 
should be recorded as AEs and reported as SAEs if meeting any seriousness criteria. 
10.8 
Methods of Recording and Assessing Adverse Events 
At each study visit, the subject will be queried on changes in his/her condition. During the 
reporting period of the study any unfavorable changes in the subject’s condition will be recorded 
as AEs, whether reported by the subject or observed by the Investigator. 
Complete, accurate and consistent data on all AEs experienced for the duration of the reporting 
period (defined below) will be reported on an ongoing basis in the appropriate section of the 
CRF. Among these AEs, all SAEs must be additionally documented and reported using an AE 
report form. It is important that each AE report include a description of the event, its duration 
(onset and resolution dates (/times “/times” to be completed when it is important to assess the 
time of AE onset relative to the recorded treatment administration time)), its severity, its 
relationship with the study treatment, any other potential causal factors, any treatment given or 
other action taken (including dose modification or discontinuation of the IPs) and its outcome. In 
addition, serious cases should be identified and the appropriate seriousness criteria documented. 
Specific guidance can be found in the CRF completion and monitoring conventions provided by 
the Sponsor. 
10.9 
Adverse Event Reporting Period 
The AE reporting period for safety surveillance begins when the subject is included into the 
study (date of first signature of informed consent) and continues through the study’s post-
treatment follow-up period, defined as 30 days from the final administration of the study 
treatment or immediately before initiation of any other anticancer therapy, whichever comes 
first. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 49 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
10.10 
Procedure for Reporting Serious Adverse Events 
In the event of any new SAE occurring during the reporting period, the Investigator must 
immediately (i.e. within a maximum of 24 HOURS after becoming aware of the event) inform 
the person(s) identified in the SAE report form by telephone, by fax or by email. When an event 
(or follow-up information) is reported by telephone, a written report must be sent immediately 
thereafter by fax or e-mail. Reporting procedures and timelines are the same for any new 
information on a previously reported SAE. For names, addresses, telephone and fax numbers for 
SAE reporting, see information included in the AE Report Form. All written reports should be 
transmitted using the AE Report Form, which must be completed by the Investigator following 
specific completion instructions. 
The AE section of the CRF must be completed and a copy of the information transmitted with 
the AE Report Form. Other relevant pages from the CRF may also be provided (e.g., medical 
history, concomitant drugs). The Investigator/Reporter must respond to any request for follow-up 
information (e.g. additional information, outcome and final evaluation, specific records where 
needed) or to any question the Sponsor may have on the AE within the same timelines as 
described for initial reports. This is necessary to permit a prompt assessment of the event by the 
Sponsor to allow for strict regulatory timelines associated with expedited safety reporting 
obligations. 
10.11 
Safety Reporting to Health Authorities, Institutional Review 
Boards and Investigators 
The Sponsor will send appropriate safety notifications to Health Authorities in accordance with 
applicable laws and regulations. The Investigator must comply with any applicable site-specific 
requirements related to the reporting of SAEs (and in particular deaths) involving his/her 
subjects to the IRB/IEC that approved the study. 
In accordance with International Conference on Harmonization (ICH) Good Clinical Practice 
(GCP) guidelines, the Sponsor will inform the Investigator of “findings that could adversely 
affect the safety of subjects, impact the conduct of the study or alter the IRB/IEC’s 
approval/favorable opinion to continue the study.” In particular and in line with respective 
regulations, the Sponsor will inform the Investigator of AEs that are both serious and unexpected 
and are considered to be related to the administered product (“suspected unexpected serious 
adverse reactions”, SUSARs). The Investigator should place copies of Safety reports in the 
Investigator Site File. National regulations with regards to safety reporting notifications to 
investigators will be taken into account. When specifically required by regulations and 
guidelines, the Sponsor will provide appropriate safety reports directly to the concerned lead 
IRB/IEC and will maintain records of these notifications. When direct reporting by the Sponsor 
is not clearly defined by national or site specific regulations, the Investigator will be responsible 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 50 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
for promptly notifying the concerned IRB/IEC of any Safety reports provided by the Sponsor and 
of filing copies of all related correspondence in the Investigator Site File. 
10.12 
Monitoring of Subjects with Adverse Events 
Any AE that occurs during the course of a clinical study and is considered to be possibly related 
to the IP must be monitored and followed up by the Investigator until stabilization or until the 
outcome is known, unless the subject is documented as “lost to follow-up”. Reasonable attempts 
to obtain this information must be made and documented. It is also the responsibility of the 
Investigator to ensure that any necessary additional therapeutic measures and follow-up 
procedures are performed. The Sponsor will actively follow-up and collect information on any 
AE that occurs during the course of a clinical study, however while this activity will continue for 
any SAEs until stabilization or until the outcome is known, it will be discontinued at the time of 
database lock for non-serious AEs. 
10.13 
Pregnancy and In Utero Drug Exposure 
Only pregnancies considered by the Investigator as related to study treatment (e.g., resulting 
from a drug interaction with a contraceptive medication) are considered as AEs. However, all 
pregnancies with an estimated conception date during the study safety period must be recorded 
by convention in the AE page/section of the CRF. The same rule applies to pregnancies in 
female subjects and in female partners of male subjects. The Investigator must notify the 
Sponsor in an expedited manner of any pregnancy using the Pregnancy Report Form, which must 
be transmitted according to the same process as described for SAE reporting. 
Investigators must actively follow up, document and report on the outcome of all these 
pregnancies, even if the subjects are withdrawn from the study. The Investigator must notify the 
Sponsor of these outcomes using the Pregnancy Report Form, and in case of abnormal outcome, 
the AE report form when the subject sustains an event and the Parent-Child/Fetus Report Form 
when the child/fetus sustains an event. 
Any abnormal outcome must be reported in an expedited manner, while normal outcomes must 
be reported within 45 days from delivery. 
In the event of a pregnancy in a subject occurring during the course of the study, the subject must 
be discontinued from study medication immediately. The Sponsor must be notified without delay 
and the subject must be followed as mentioned above. 
10.14 
Laboratory Assessments 
All clinical safety laboratory tests listed in the section below will be performed at local 
laboratories. Subject eligibility will be determined based on the baseline laboratory results. 
Clinically significant laboratory test abnormalities will be followed until resolution or 
stabilization and the overall clinical outcome has been ascertained (See Section 10.4). 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 51 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Blood samples will be collected for the following clinical laboratory tests: 
• Serum Chemistry: aspartate aminotransferase (AST), ALT, total bilirubin, creatinine, 
blood urea nitrogen (BUN), potassium and calcium 
• Hematology: hemoglobin, reticulocytes, platelets, WBCs, neutrophils, neutrophil 
precursors (promyelocytes, myelocytes, metamyelocytes, band neutrophils), monocytes, 
lymphocytes and blasts.  
• Coagulation: activated partial thromboplastin time (APTT), prothrombin 
time/international normalized ratio (PT/INR) 
 
 
 
 
 
 
 
 
11 
STUDY PROCEDURES 
11.1 
Screening and Baseline Assessments 
A signed Informed Consent Form (ICF) must be obtained before any study-specific screening 
evaluations are performed and should be documented in the subject’s medical chart. 
The following evaluations and procedures will be performed within 28 days prior to the first 
study drug administration (Cycle 1 Day 1). Any screening evaluation, including disease status, 
will need to be repeated if performed more than 28 days from Cycle 1 Day 1. Evaluations 
performed as part of the standard of care within 28 days of dosing but prior to consent, do not 
need to be repeated. By signing the consent form, the subject agrees to the collection of this 
health information. 
• Obtain signed ICF and form for the HIPAA/Data Protection Act  
• Record subject’s medical history, including demographics, primary diagnosis and WHO 
classification (Table 8), outcome and duration of response to prior cancer therapy and any 
ongoing AEs 
• Record the number of RBC, whole blood and platelet transfusions for the 4 months prior 
to Cycle 1 Day 1. 
• Record concomitant medications 
• Record subject height 




Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 53 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
11.2 
Day 1 of Cycle 1 
The following assessments will be conducted before the first dose of tipifarnib on Day 1 of Cycle 
1: 
• Record any RBC, whole blood and platelet transfusions that were received between the 
screening visit and Cycle 1 Day 1. 
• Record concomitant medications 
• Assessment of AEs 
• Assess ECOG performance status. 
• If not collected within the 14 days prior to Cycle 1 Day 1 as specified in Section 11.1, 
record subject’s weight and vital signs 
• Symptom based physical examination 
• Perform serum chemistry laboratory tests (AST, ALT, total bilirubin, creatinine, BUN, 
potassium and calcium).  Subjects are not required to be fasting.  Serum chemistry tests 
do not need to be repeated on Cycle 1 Day 1 if the screening laboratory tests were 
conducted within 72 hours prior to the first dose of tipifarnib.   
• Perform hematology tests: hemoglobin, reticulocytes, platelets, WBCs, neutrophils, 
neutrophil precursors (promyelocytes, myelocytes, metamyelocytes, band neutrophils), 
monocytes, lymphocytes and blasts.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subjects will self-administer the first dose of tipifarnib with food in the evening. On Day 1 of 
Cycle 1, only 1 dose of tipifarnib will be administered.  Thereafter, subjects will continue to self-
administer tipifarnib twice a day (approximately every 12 hours, same time every morning and 
evening, with food) based on their assigned dose regimen. The interval between dosing should 
not be less than 6 hours. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 54 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
11.3 
Day 1 (± 2 days) of Cycle 2 and every cycle thereafter 
The following assessments will be conducted: 
• Record any RBC, whole blood and platelet transfusions that were received since the last 
study visit. 
• Record concomitant medications 
• Assessment of AEs 
• Assess ECOG performance status. 
• Symptom based physical examination 
• Perform urine or serum pregnancy test for females of child-bearing potential only 
• Perform serum chemistry laboratory tests (AST, ALT, total bilirubin, creatinine, BUN, 
potassium and calcium).  Subjects are not required to be fasting.  If clinically indicated, 
serum chemistry tests may be repeated more frequently. 
• Perform hematology tests: hemoglobin, reticulocytes, platelets, WBCs, neutrophils, 
neutrophil precursors (promyelocytes, myelocytes, metamyelocytes, band neutrophils), 
monocytes, lymphocytes and blasts.  If clinically indicated, hematology tests may be 
repeated more frequently. 
 
 
 
 
 
 
 
 
 
 
• Conduct a drug accountability on the returned empty bottles and unused medications. 
11.4 
Day 22 (± 5 days) of Cycles 3 and every approximately 12 
weeks thereafter (e.g. 6, 9, 12, etc.) 
The timing of the hematologic and disease assessments should be maintained as much as 
possible independently of potential treatment cycle delays. 
The following procedures will be performed during the Day 22 visit: 
• Record any RBC, whole blood and platelet transfusions that were received since the last 
study visit. 
• Record concomitant medications 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 55 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
• Assessment of AEs 
• Symptom based physical examination 
• Perform hematology tests: hemoglobin, reticulocytes, platelets, WBCs, neutrophils, 
neutrophil precursors (promyelocytes, myelocytes, metamyelocytes, band neutrophils), 
monocytes, lymphocytes and blasts 
• Perform disease and response assessment: 
o Perform bone marrow aspirate for disease assessment, cytogenetic assessment and 
NGS oncogene panel during Cycles 3, 6 and 9 only.  Thereafter, bone marrow 
evaluations will occur as per institutional standard practice.  If the bone marrow 
aspirate is inadequate, a bone marrow biopsy should be performed. If on this bone 
marrow sample, a CR or PR is observed, a bone marrow aspirate with cytogenetic 
assessment must be repeated 1 month later, i.e. prior to the end of the next cycle. 
o Investigator review of subject RBC transfusions, hematology and bone marrow 
evaluation (if available) for completion of response assessment. 
 
 
 
 
 
  
11.5 
End of Treatment Visit 
The following assessments will occur approximately 30 days (30 ± 7 days) after the last 
administration of study drug or immediately before the administration of another anticancer 
drug, whichever takes place first: 
• Record any RBC, whole blood and platelet transfusions that were received since the last 
study visit. 
• Record concomitant medications 
• Assessment of AEs 
• Assess ECOG performance status. 
• Record subject weight 
• Collect vital signs (heart rate, blood pressure, temperature) 
• Complete physical examination  
• Perform urine or serum pregnancy test for females of child-bearing potential only 
• Perform serum chemistry laboratory tests (AST, ALT, total bilirubin, creatinine, BUN, 
potassium and calcium).  Subjects are not required to be fasting.   


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 56 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
• Perform hematology tests: hemoglobin, reticulocytes, platelets, WBCs, neutrophils, 
neutrophil precursors (promyelocytes, myelocytes, metamyelocytes, band neutrophils), 
monocytes, lymphocytes and blasts 
• Perform coagulation tests (APTT, PT/INR) 
• Perform disease and response assessment: 
o Perform bone marrow aspirate for disease assessment, cytogenetic assessment and 
NGS oncogene panel as part of the End of Treatment visit if the visit occurs 
during the first 9 months from the start of the subject’s participation in the study.  
Thereafter, bone marrow evaluations will occur during End of Treatment visit in 
accordance with institutional standard practice.  If the bone marrow aspirate is 
inadequate, a bone marrow biopsy should be performed. If on this bone marrow 
sample, a CR or PR is observed, a bone marrow aspirate with cytogenetic 
assessment must be repeated 1 month later. 
o Investigator review of subject RBC transfusions, hematology and bone marrow 
evaluation (if available) for completion of response assessment. 
 
 
 
 
  
 
 
• Conduct drug accountability on the returned empty bottles and unused medications. 
11.6 
Post Treatment Follow up 
11.6.1 
Subjects who Terminate Treatment for Reasons other than 
Death or Disease Progression 
Subjects who terminated treatment for reasons other than death or disease progression will be 
assessed at regular intervals for disease progression and leukemic transformation.  
The assessments to be conducted at each monthly visit are: 
• Perform hematology tests (hemoglobin, platelets, WBCs, neutrophils, neutrophil 
precursors, monocytes, lymphocytes and blasts) 
The assessments to be conducted at each approximately every 12 weeks visit are  
• Record any RBC, whole blood and platelet transfusions that were received since the last 
study visit. 
• Perform disease and response assessment: 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 57 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
o Perform bone marrow aspirate as part of the assessments if post-treatment follow-
up visit is conducted during the first 9 months from the start of the subject’s 
participation in the study.  Thereafter, bone marrow evaluations will occur during 
post-treatment follow-up visits in accordance with institutional standard practice.  
If the bone marrow aspirate is inadequate, a bone marrow biopsy should be 
performed. If on this bone marrow sample, a CR or PR is observed, a bone 
marrow aspirate with cytogenetic assessment must be repeated 1 month later. 
o Investigator review of subject RBC transfusions, hematology and bone marrow 
evaluation (if available) for completion of response assessment. 
• Assessments of AEs and concomitant medications may also be conducted if AEs were 
not resolved at the time of the End of Treatment visit. 
11.6.2 
Follow Up after Disease Progression 
Upon disease progression, all subjects in the study will be followed approximately every 12 
weeks for survival and the use of subsequent therapy until either death or 12 months after accrual 
of the study cohort has been completed, whichever occurs first. Information on survival and 
subsequent anticancer therapy may be collected by phone. 
12 
STATISTICAL METHODS  
This section outlines the statistical analysis strategy and procedures for the study. Specific details 
of the primary and key secondary analyses will be provided in the Statistical Analysis Plan 
(SAP). If, after the study has begun, but prior to the final analysis, important changes are made to 
the protocol that affect principal features of the primary or key secondary analyses, then the 
protocol and/or SAP will be amended, as appropriate. Any other changes made to the planned 
analyses after the protocol and SAP have been finalized, along with an explanation as to when 
and why they occurred, will be listed in the Clinical Study Report (CSR) for the study. Post hoc 
exploratory analyses will be clearly identified in the CSR. 
12.1 
Populations 
12.1.1 
Efficacy Analysis 
The full analysis set (FAS) will serve as the primary population for the analysis of ORR and 
other efficacy-related data. Prior to Amendment 2 (version 20 Dec 2016), other subjects were 
enrolled into the trial using a different dose regimen.  Also, for inclusion in the FAS, subjects 
must meet all Amendment 3 inclusion criteria. For the purposes of the primary analysis 
(advancement from stage 1 to stage 2 and overall analysis for each dose regimen cohort), those 
subjects will not be included.  The excluded subject data will be summarized separately in the 
reporting of the study. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 58 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Therefore, subjects will be excluded from the FAS for the following reasons: 
• Did not meet eligibility criteria as outlined in Amendment 3 (version 09 Jul 2017) 
• Failure to receive at least one dose of tipifarnib 
• No post-baseline endpoint data subsequent to at least 1 dose of study drug 
• Enrolled prior to Amendment 2 (version 20 Dec 2016) 
A supportive analysis may be performed on the Per-Protocol population which excludes subjects 
due to important deviations from the protocol that may substantially affect the results of the 
primary analysis, such as not taking at least 80% of the intended dose in cycle 1. The final 
determination on protocol violations, and thereby the composition of the Per-Protocol 
population, will be made prior to locking the clinical database and final analysis and will be 
documented in a separate memorandum. 
12.1.2 
Safety Analysis 
The All Subjects as Treated (ASaT) population will be used for the analysis of safety data. The 
ASaT population consists of all enrolled subjects who receive at least one dose of tipifarnib. At 
least one laboratory or vital sign measurement obtained subsequent to at least one dose of study 
drug is required for inclusion in the analysis of a specific safety parameter. To assess change 
from baseline, a baseline measurement is also required. 
12.2 
Endpoints 
12.2.1 
Efficacy 
Disease response assessment will be performed by the Investigator according to the MDS IWG 
criteria (Table 9 and Table 10).   
For the evaluation of the primary endpoint (i.e. ORR) to determine advancement to the second 
stage of the study (i.e. enrollment of 7 additional subjects in the dose regimen cohort) and overall 
outcome of the study, each dose regimen cohort will be evaluated independently.   
Transfusion independence and disease response will be summarized descriptively per dose 
regimen cohort and overall.    
The objective response rate will be estimated and includes the following response types: CR, PR, 
marrow CR and HI according to the MDS IWG criteria (Table 9 and Table 10).  The estimate of 
the objective response rate will be calculated based on the maximum likelihood estimator (i.e., 
crude proportion of subjects whose best overall response is CR, PR, marrow CR or HI). The 
estimate of the objective response rate will be accompanied by 2-sided 95% exact binomial 
confidence intervals.  


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 59 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
The duration of objective response will be calculated for subjects who achieve CR, PR, marrow 
CR or HI. For such subjects, the duration of objective response is defined as the number of days 
from the start date of response (whichever response is achieved first) to the first date that 
progressive disease is objectively documented. Disease progression will be determined by the 
Investigator using MDS IWG criteria (Table 10). The duration of objective response will be 
right-censored for subjects who achieve a response and meet 1 of the following conditions: 1) 
non-protocol anticancer treatment started before documentation of disease progression, 2) death 
or documented disease progression after more than 1 missed disease assessment visit, or 3) alive 
and does not have documentation of disease progression before a data analysis cutoff date.   
The duration of objective response will be summarized descriptively using the Kaplan-Meier 
method. The 50th percentile of the Kaplan-Meier distribution will be used to estimate the median 
response duration.  
Progression free survival will be defined as the time (in months) from enrollment to either first 
observation of progressive disease or occurrence of death due to any cause within 1 year 
(approximately 4 time intervals for disease assessments) of either first administration of 
tipifarnib or the last disease assessment. Similarly, survival will be defined as the time (in 
months) from enrollment to occurrence of death due to any cause within 1 year (approximately 4 
time intervals for disease assessments) of either first administration of tipifarnib or the last 
disease assessment.  
Determination of RBC TI will be assessed by the Investigator through the review of subject 
transfusion requirements and hemoglobin levels.  RBC TI will be defined as the absence of the 
intravenous infusion of any RBC transfusion during any consecutive “rolling” 56 days during the 
treatment period, i.e. days  1 to 56, days 2 to 57, days 3 to 58, etc. and a ≥ 1 g/dL increase in 
hemoglobin level.  The rise in the hemoglobin concentration in subjects who no longer require 
transfusions will be calculated as the difference between the maximum hemoglobin 
concentration and the minimum pre-transfusion value during the 12 weeks before enrollment in 
the study. 
12.2.2 
Safety and Tolerability  
Safety and tolerability of tipifarnib will be assessed based on the following: 
• Incidence, duration, and severity of TEAEs, SAEs, AEs resulting in permanent 
discontinuation of study drug, and deaths within approximately 30 days from the last 
dose of study drug (or immediately before the administration of another anticancer 
treatment) 
• Changes in laboratory test results 
AEs will be coded using the latest available version of the Medical Dictionary for Regulatory 
Activities (MedDRA). TEAEs are defined as AEs that start on or after the first dose of study 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 60 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
drug and within approximately 30 days of the last administration of study drug. AEs will be 
summarized by the number and percentage of subjects who experienced the event, according to 
system organ class and preferred term. A subject reporting multiple cases of the same AE will be 
counted once within each system organ class and similarly counted once within each preferred 
term. 
Unless specified otherwise, the denominator for these calculations will be based on the number 
of subjects in each cohort who received at least one administration of tipifarnib, irrespective of 
the total number of doses or treatment cycles administered. These conventions will be 
appropriately modified to calculate AE incidence rates separately for each cycle that study 
therapy is administered. AE incidence rates may also be calculated based on other measures of 
subject exposure (e.g., total number of treatment cycles administered). AEs will also be 
summarized by NCI CTCAE v.4.03 severity grade, by relationship to each study drug and by 
treatment regimen. Additional summaries may also be provided for SAEs, and events resulting in 
the permanent discontinuation of therapy. All AEs will be included in individual subject listings. 
The incidence of grade 3 and 4 hematological toxicities (including neutropenia, 
thrombocytopenia, and anemia) will be provided by treatment cycle and across all treatment 
cycles. The toxicity grades for laboratory tests will be based on NCI CTCAE v.4.03 criteria. The 
use of blood transfusions (platelets, red blood cells, whole blood) and/or growth factor support 
will be reported.  
Vital sign results (heart rate, blood pressure and temperature) will be summarized descriptively 
for each scheduled and unscheduled protocol time point. Changes will be calculated relative to 
the assessments at baseline. 
 
 
 
 
 
 
 
 
 
 
12.4 
Sample Size Determination 
A two-stage study design was selected in order to minimize the number of study subjects treated 
if tipifarnib were considered not sufficiently efficacious to grant further development in this 
subject population. This design is intended to allow the termination of accrual in case of 
unacceptably low efficacy as measured by ORR and will be evaluated in a FAS basis.   


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 61 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
In the first stage, 22 eligible subjects will be enrolled and randomized in to one of two dose 
regimen cohorts (11 subjects per cohort). If two or more responses are observed in a given dose 
regimen cohort, 7 additional study subjects will be enrolled.  Each dose regimen cohort is 
designed to test the null hypothesis of ORR rate less than 10% vs alternative hypothesis of ORR 
rate at least 30% and will be evaluated independently.  At the completion of the study, treatment 
will be considered of further interest if 4 or more subjects in the 18 subject dose regimen cohort 
achieve a response, i.e. the true ORR is higher than 10%.  
To determine the total trial size, a response of interest of 30% is assumed. This design provides 
80% power to detect a difference between 10% and 30% RBC TI rate at one-sided significance 
level of 0.087. Using this design, the probability of terminating each stratum at the end of stage 1 
if the true rate is 10% is 0.697 while the probability of terminating each stratum at the end of 
stage 1 if the true rate is 30% is 0.113. 
The performance characteristics of this approach are shown in Table 7. 
Table 6: Performance characteristics for sample size determination 
  
Probability to conclude TRUE rate > 0.10 if TRUE underlying 
RBC TI response rate is as indicated 
TRUE Rate --> 
0.1 
0.3 
0.4 
N=11 
0.09 
0.69 
0.88 
N=18 
0.1 
0.83 
0.97 
N=25 
0.1 
0.91 
0.99 
N=32 
0.09 
0.95 
>0.99 
12.5 
Changes in the Conduct of the Study or Planned Analyses 
Only the Sponsor, upon consultation with the principal Investigator may modify the protocol. 
The Sponsor will issue a formal protocol amendment to implement any changes. The only 
exception is when an Investigator considers that a subject’s safety is compromised without 
immediate action. In these circumstances, immediate approval of the chairman of the IRB/IEC 
must be sought, and the Investigator should inform the Sponsor and the full IRB/IEC within 2 
working days after the emergency has occurred. 
The IRB/IEC must review and approve all protocol amendments. Protocol amendments that have 
an impact on subject risk or the study objectives, or require revision of the ICF, must receive 
approval from the IRB/IEC prior to their implementation. 
When a protocol amendment substantially alters the study design or the potential risks or burden 
to subjects, the ICF will be amended and approved by the Sponsor and the IRB/IEC, and all 
active subjects must again provide informed consent. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 62 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
13 
ETHICAL AND REGULATORY ASPECTS 
13.1 
Responsibilities of the Investigator 
The Investigator is responsible for the conduct of the study at his/her site. He/she will ensure that 
the study is performed in accordance with the clinical study protocol and with the ethical 
principles that have their origin in the Declaration of Helsinki, as well as with the ICH Note for 
Guidance on Good Clinical Practice (ICH Topic E6, 1996) and applicable regulatory 
requirements. In particular, the Investigator must ensure that only subjects who have given their 
informed consent are included into the study. 
13.2 
Subject Information and Informed Consent 
An unconditional prerequisite for a subject’s participation in the study is his/her written informed 
consent. The subject’s written informed consent to participate in the study must be given before 
any trial-related activities are carried out.  
Adequate information must therefore be given to the subject by the Investigator before informed 
consent is obtained (a person designated by the Investigator may give the information, if 
permitted by local regulations). 
With the cooperation of the Sponsor, and in accordance with the Note for Guidance on Good 
Clinical Practice (ICH Topic E6, 1996), and the ethical principles that have their origin in the 
Declaration of Helsinki, the Investigator will prepare the informed consent form and other 
written information to be used in obtaining informed consent from the study subjects. The 
Investigator should cooperate with the sponsor for preparation of aforementioned written 
information. 
Before the consent may be obtained, the potential subject (or the potential subject’ legally 
acceptable representative) should be provided with sufficient time and opportunity to be accessed 
to the details of clinical study and to decide if they would participate in the study. All the queries 
related to the study from the potential subject or legally acceptable representative should be 
answered by the Investigator or collaborators. 
In addition to providing this written information to a potential subject, the Investigator or his/her 
designee will inform the subject verbally of all pertinent aspects of the study. The language used 
in doing so must be chosen so that the information can be fully and readily understood by lay 
persons. 
Depending on local regulations, a person other than the Investigator may inform the subject and 
sign the ICF. Where the information is provided by the Investigator, the ICF must be signed and 
personally dated by the subject and the Investigator. The signed and dated declaration of 
informed consent will remain at the Investigator’s site, and must be safely archived by the 
Investigator so that the forms can be retrieved at any time for monitoring, auditing and inspection 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 63 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
purposes. A copy of the signed and dated information and ICF should be provided to the subject 
prior to participation. 
Whenever important new information becomes available that may be relevant to the subject’s 
consent, the written subject information sheet and any other written information provided to 
subjects will be revised by the Sponsor and be submitted again to the IRB/IEC for review and 
favorable opinion. The agreed, revised information will be provided to each subject in the study 
for signing and dating. The Investigator will explain the changes to the previous version. 
13.3 
Subject Identification and Privacy 
A unique subject number will be assigned to each subject at inclusion, immediately after 
informed consent has been obtained. This number will serve as the subject’s identifier in the 
study as well as in the clinical study database. 
The subject’s data collected in the study will be stored under this number. Only the Investigator 
will be able to link the subject’s study data to the subject via an identification list kept at the site. 
The subject’s original medical data that are reviewed at the site during source data verification 
by the Monitor, audits and Health Authority inspections will be kept strictly confidential. 
Data protection and privacy regulations will be observed in capturing, forwarding, processing, 
and storing subject data. Subjects will be informed accordingly, and will be requested to give 
their consent on data handling procedures in accordance with national regulations. 
13.4 
Emergency Medical Support and Subject Card 
Subjects enrolled in this clinical study will be provided with Emergency Medical Support cards 
during their study participation, which will be provided by the Sponsor or designee. The 
Emergency Medical Support card is based on the need to provide clinical study subjects with a 
way of identifying themselves as participating in a clinical study, and subsequently to give health 
care providers access to the information about this participation that may be needed to determine 
the course of the subject’s medical treatment. 
This service is designed to provide information to health care providers who are not part of the 
clinical study. Clinical study investigators, who are already aware of the clinical study protocol 
and treatment, have other means of accessing the necessary medical information for the 
management of emergencies occurring in their subjects. 
The first point of contact for all emergencies will be the clinical study Investigator caring for the 
affected subject. The Investigator agrees to provide his or her emergency contact information on 
the card for this purpose. If the Investigator is available when an event occurs, s/he will answer 
any questions. Any subsequent action will follow the standard processes established for the 
Investigators. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 64 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
In cases where the Investigator is not available, the Sponsor or designee will provide a 24 hour 
contact number whereby health care providers will be given access to the appropriate Sponsor’s 
physician or designee to assist with any information regarding tipifarnib in case of a medical 
emergency. 
13.5 
Clinical Trial Insurance and Compensation to Subjects 
The Sponsor is entirely responsible for AEs that are associated with this study and cause damage 
to the health of the subjects, except for AEs caused by an intentional and/or significant deviation 
on the part of the Investigator, the study site, and/or the subject. Insurance coverage shall be 
provided for participating in the study. Insurance conditions shall meet good local standards, as 
applicable. 
13.6 
Institutional Review Board/Independent Ethics Committee 
Prior to commencement of the study at a given site, the clinical study protocol will be submitted 
together with its associated documents (Investigator’s brochure, Subject Information and ICFs) 
to the responsible IRB/IEC for its favorable opinion/approval. The written favorable 
opinion/approval of the IRB/IEC will be filed in the Investigator Site File, and a copy will be 
filed in the Trial Master File at the Sponsor. 
The study must not start at a site before the Sponsor has obtained written confirmation of 
favorable opinion/approval from the concerned IRB/IEC. The IRB/IEC will be asked to provide 
documentation of the date of the meeting at which the favorable opinion/approval was given, and 
of the members and voting members present at the meeting. Written evidence of favorable 
opinion/approval that clearly identifies the study, the clinical study protocol version and the 
Subject Information and ICF version reviewed should be provided. Where possible, copies of the 
meeting minutes should be obtained. 
Amendments to the clinical study will also be submitted to the concerned IRB/IEC, before 
implementation in case of substantial changes. Relevant safety information will be submitted to 
the IRB/IEC during the course of the study in accordance with national regulations and 
requirements. 
13.7 
Communication to Health Authorities 
The clinical study protocol and its amendments and any applicable documentation (e.g. 
Investigator’s Brochure, Subject Information and ICF) will be submitted or notified to the Health 
Authorities. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 65 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
14 
TRIAL MANAGEMENT 
14.1 
Case Report Form Management 
The Investigator or designee will be responsible for entering study data in the CRFs that will be 
provided by the Sponsor or its designee. It is the Investigator’s responsibility to ensure the 
accuracy of the data entered in the CRFs. Database lock will occur once quality control and 
quality assurance procedures (if applicable) have been completed.  
14.2 
Source Data and Subject Files 
The Investigator must keep a subject file (medical file, original medical records) on paper or 
electronically for every subject included in the study. This file will contain the available 
demographic and medical information for the subject, and should be as complete as possible.  
In particular, the following data should be available in this file: 
• Subject’s full name 
• Date of birth 
• Gender 
• Height 
• Weight 
• Relevant medical history and concomitant diseases 
• Prior and concomitant therapies (including changes during the study) 
• Trial identification  
• Date of subject’s inclusion into the study (i.e. date of informed consent) 
• Subject identifier in the study 
• Dates of the subject’s visits to the site 
• Dates and number of RBC, whole blood and platelet transfusions 
• Any medical examinations and clinical findings predefined in the clinical study protocol 
• All AEs observed in the subject 
• Date of subject’s end of study, and 
• Date of and reason for early withdrawal of the subject from the study or from treatment, 
if applicable. 
It must be possible to identify each subject by using this subject file. Additionally, any other 
documents containing source data must be filed. This includes original printouts of data recorded 
or generated by automated instruments, bone marrow evaluation, laboratory value listings, etc. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 66 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Such documents must bear at least the subject identifier and the date when the procedure was 
performed. Information should be printed by the instrument used to perform the assessment or 
measurement, if possible. Information that cannot be printed by an automated instrument will be 
entered manually. Medical evaluation of such records should be documented as necessary and 
the documentation signed and dated by the Investigator. 
The following information described in the CRFs is regarded as the source data: 
• Any Investigator’s comments 
• Subject identifier 
• Information on AEs (e.g. seriousness, severity, outcome, and causality to the IP) 
• Reason for providing concomitant medications and procedures (if applicable) 
• Assessment of disease response 
• Description about study discontinuation 
14.3 
Investigator Site File and Archiving 
The Investigator will be provided with an Investigator Site File upon initiation of the study. This 
file will contain all documents necessary for the conduct of the study and will be updated and 
completed throughout the study. It must be available for review by the Monitor, and must be 
ready for audit by the Sponsor as well as for inspection by Health Authorities during and after 
the study, and must be safely archived for at least 15 years (or per local requirements or as 
otherwise notified by the Sponsor) after the end of the study. The documents to be thus archived 
include the Subject Identification List and the signed subject ICFs. If archiving of the 
Investigator Site File is no longer possible at the site, the Investigator must notify the Sponsor. 
All original subject files (medical records) must be stored at the site (hospital, research institute, 
or practice) for the longest possible time permitted by the applicable regulations, and/or as per 
ICH GCP guidelines or ordinance of GCP, whichever is longer. In any case, the Investigator 
should ensure that no destruction of medical records is performed without the written approval of 
the Sponsor. 
14.4 
Monitoring, Quality Assurance and Inspection by Health 
Authorities 
This study will be monitored in accordance with the ICH Note for Guidance on Good Clinical 
Practice (ICH Topic E6, 1996). The site Monitor will perform visits to the study site at regular 
intervals. 
The Sponsor, as well as Health Authorities, must be permitted to inspect all study-related 
documents and other materials at the site, including the Investigator Site File, the completed 
CRFs, the IP(s), and the subjects’ original medical records/files. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 67 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
The clinical study protocol, each step of the data captures procedure, and the handling of the 
data, including the final clinical study report, will be subject to independent Quality Assurance 
activities. Audits may be conducted at any time during or after the study to ensure the validity 
and integrity of the study data. 
14.5 
Changes to the Clinical Trial Protocol 
Changes to the clinical study protocol will be documented in written protocol amendments. 
Major (substantial, significant) amendments will usually require submission to the Health 
Authorities and to the relevant IRB/IEC for approval or favorable opinion. In such cases, the 
amendment will be implemented only after approval or favorable opinion has been obtained. 
Minor (non-substantial) protocol amendments, including administrative changes, will be filed by 
the Sponsor and by the Investigator at the clinical study site. They will be submitted to the 
relevant IRB/IEC or to Health Authorities only where requested by pertinent regulations. 
Any amendment that could have an impact on the subject’s agreement to participate in the study 
requires the renewal of the subject’s informed consent prior to implementation. 
14.6 
Clinical Trial Report 
After completion of the study, a clinical study report according to ICH E3 will be generated by 
the Sponsor in consultation with the Principal Investigator. 
14.7 
Publication 
The first publication will be a publication of the results of the analysis of the primary endpoint 
and will include data from all study sites. Lead investigators will be identified based on accrual 
and Good Publication Practices and the decision to publish or present the initial data from all the 
study sites, or a presentation indicating the design or progress of the study, will reside in the 
Sponsor in consultation with the lead investigators. Publications or presentations prior to the 
generation of a final clinical study report will be clearly marked as preliminary reports. 
Investigators will inform the Sponsor in advance about any subsequent plans to publish or 
present data from any portion of the study. Any publications or presentations of the results 
(abstracts in journals or newspapers, oral presentations, etc.), either in whole or in part, by 
investigators or their representatives will require a pre-submission review by the Sponsor. The 
Sponsor will not suppress or veto publications, but will maintain the right to a reasonable delay 
of a publication in order to protect intellectual property rights. 
15 
References 
Baines AT, Xu D, Der CJ. Inhibition of RAS for cancer treatment: the search continues. Future 
Med Chem. 2011 Oct;3(14):1787-808. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 68 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Barrett J, Saunthararajah Y, Molldrem J.  Myelodysplastic syndrome and aplastic anemia: 
distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000 
Jan;37(1):15-29. 
Chamuleau ME, Westers TM, van Dreunen L, et.al. Immune mediated autologous cytotoxicity 
against hematopoietic precursor cells in patients with myelodysplastic syndrome. 
Haematologica. 2009 Apr;94(4):496-506. 
Cheson BD, Bennett JM, Kantarjian H et al. Report of an international working group to 
standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-4. 
Cheson BD, Greenberg PL, Bennett JM, et. al. Clinical application and proposal for modification 
of the International Working Group (IWG) response criteria in myelodysplasia.  Blood 2006 Jul 
15;108(2):419-425. 
Cheson BD, Zwiebel JA, Dancey J, Murgo A. Novel therapeutic agents for the treatment of 
myelodysplastic syndromes. Sem Oncol 2000;27(5):560-77. 
Dayyani R, Conley A, Strom S, et. al. Cause of Death in Patients With Lower-Risk 
Myelodysplastic Syndrome. Cancer 2010;116(9):2174-2179. 
Epling-Burnette PK, Bai F, Painter JS, et. al. Reduced natural killer (NK) function associated 
with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK 
receptors. Blood. 2007 Jun 1;109(11):4816-24. Epub 2007 Mar 6. 
Epling-Burnette PK, Sokol L, Chen X, et. al. Clinical improvement by farnesyltransferase 
inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor 
signaling. Blood. 2008 Dec 1;112(12):4694-8.  
Fenaux P, Morel P, Laï JL. Cytogenetics of myelodysplastic syndromes. Sem Hematol 
1996;33:127-38. 
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et. al. Efficacy of azacitidine compared with that of 
conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a 
randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223-32 
Fenaux P, Raza A, Mufti GJ, et. al. A multicenter phase 2 study of the farnesyltransferase 
inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood. 2007 May 
15;109(10):4158-63.  
Greenberg P, Stone R, Al-Kali A, et. al. NCCN Clinical Practice Guidelines in Oncology: 
myelodysplastic syndromes. Version 1.2016, 05/28/15. 
Jones DC, Edgar RS, Ahmad T, et. al.  Killer Ig-like receptor (KIR) genotype and HLA ligand 
combinations in ulcerative colitis susceptibility.  Genes Immun. 2006 Oct;7(7):576-82. 
Epub 2006 Aug 24. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 69 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Kaminskas E, Farrell AT, Wang Y-C, Sridhara R, Pazdur R. FDA drug approval summary: 
azacitidine (5-azacytidine, Vidaza™) for injectable suspension. Oncologist 2005;10:176-182. 
Kanchan K, Loughran TP Jr.  Antigen-driven clonal T cell expansion in disorders of 
hematopoiesis. Leuk Res. 2003 Apr;27(4):291-2. 
Kantarjian H, Issa JP, Rosenfeld CS, et. al. Decitabine improves patient outcomes in 
myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006 Apr 
15;106(8):1794-803. 
Kerbauy DB, Deeg HJ.  Apoptosis and antiapoptotic mechanisms in the progression of 
myelodysplastic syndrome. Exp Hematol. 2007 Nov;35(11):1739-46. 
Kirschbaum MH, Synold T, Stein AS, et. al. A phase 1 trial dose-escalation study of tipifarnib on 
a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia. 
2011 Oct;25(10):1543-7.  
Kitagawa M, Kamiyama R, Kasuga T.  Increase in number of bone marrow macrophages in 
patients with myelodysplastic syndromes. Eur J Haematol. 1993 Jul;51(1):56-8. 
Kook H, Zeng W, Guibin C, et. al.  Increased cytotoxic T cells with effector phenotype in 
aplastic anemia and myelodysplasia. Exp Hematol. 2001 Nov;29(11):1270-7. 
Kurzrock R, Albitar M, Cortes JE, et. al. Phase II study of R115777, a farnesyl transferase 
inhibitor, in myelodysplastic syndrome. J Clin Oncol. 2004 Apr 1;22(7):1287-92. 
Kurzrock R, Kantarjian HM, Blascovich MA, et. al. Phase I study of alternate-week 
administration of tipifarnib in patients with myelodysplastic syndrome. Clin Cancer Res. 2008 
Jan 15;14(2):509-14. 
Kurzrock R, Kantarjian HM, Cortes JE, et. al. Farnesyltransferase inhibitor R115777 in 
myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003 
Dec 15;102(13):4527-34. 
List A, Dewald G, Bennett J, et. al. Lenalidomide in the myelodysplastic syndrome with 
chromosome 5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65. 
Lowe DP, Cook MA, Bowman SJ, et. al. UK Sjögren's Interest Group.  Association of killer cell 
immunoglobulin-like receptors with primary Sjogren's syndrome. Rheumatology (Oxford). 2009 
Apr;48(4):359-62.  
Lübbert M, Suciu S, Baila L, et. al. Low-dose decitabine versus best supportive care in elderly 
patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive 
chemotherapy: final results of the randomized phase III study of the European Organisation for 
Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin 
Oncol. 2011 May 20;29(15):1987-96. 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 70 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Maciejewski JP, Risitano AM, Sloand EM, et. al. A pilot study of the recombinant soluble 
human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic 
syndrome. Br J Haematol. 2002 Apr;117(1):119-26. 
Martinelli G, Iacobucci I, Paolini S, et. al. Farnesyltransferase inhibition in hematologic 
malignancies: the clinical experience with tipifarnib. Clin Adv Hematol 
Oncol. 2008 Apr;6(4):303-10. 
Moesta AK, Parham P.  Diverse functionality among human NK cell receptors for the C1 epitope 
of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Front Immunol. 2012 Nov 22;3:336.  
Molldrem JJ, Caples M, Mavroudis D, et. al. Antithymocyte globulin for patients with 
myelodysplastic syndrome. Br J Haematol. 1997 Dec;99(3):699-705. 
Momot et al. Haematologica 2008, 93(s1):276 Abs.0689. 
Momot T, Koch S, Hunzelmann N, et. al.  Association of killer cell immunoglobulin-like 
receptors with scleroderma. Arthritis Rheum. 2004 May;50(5):1561-5. 
National Cancer Institute. SEER Cancer Statistics Review 1975 – 2012: Section 30 – 
Myelodysplastic Syndromes (MDS), Chronic Myeloproliferative Disorders (CMD), and Chronic 
Myelomonocytic Leukemia (CMML). 2012. Available at 
http://seer.cancer.gov/csr/1975_2012/results_single/sect_30_table.02.pdf.  Accessed August 19, 
2015. 
Oosterveld M, de Witte T. Intensive treatment strategies in patients with high risk 
myelodysplastic syndrome and secondary acute myeloid leukemia. Blood Rev 2000;14:182-9. 
Painter et al. Blood [ASH Annual Meeting Abstracts] 2011; 118: Abstract 2412. 
Passweg JR, Giagounidis AA, Simcock M, et. al. Immunosuppressive therapy for patients with 
myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing 
antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin 
Oncol. 2011 Jan 20;29(3):303-9. 
Raza A, Reeves JA, Feldman EJ, et. al. Phase 2 study of lenalidomide in transfusion-dependent, 
low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 
5q. Blood. 2008 Jan 1;111(1):86-93.  
Saba H, Rosenfeld C, Issa J, et. al. First Report of the Phase III North American Trial of 
Decitabine in Advanced Myelodysplastic Syndrome (MDS). Blood (ASH Annual Meeting 
Abstracts) 2004 104: Abstract 67. 
Saif MW, Hopkins JL, Gore SD.  Autoimmune phenomena in patients with myelodysplastic 
syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 2002 Nov;43(11):2083-92. 
Salim PH, Jobim M, Bredemeier M., et al. Killer cell immunoglobulin-like receptor (KIR) genes 
in systemic sclerosis. Clin Exp Immunol. 2010 Jun;160(3): 325-30.  


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 71 of 79 
 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
Serio et al. Blood [ASH Annual Meeting Abstracts] 2006 108: Abstract 2670. 
Silverman LR, Demakos EP, Peterson BL, et. al. Randomized controlled trial of azacitidine in 
patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin 
Oncol. 2002 May 15;20(10):2429-40. 
Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles 
of immunity in suppressing tumor development and shaping tumor immunogenicity.  Adv 
Immunol. 2006;90:1-50. 
Sugimori C, List AF, Epling-Burnette PK. Immune dysregulation in myelodysplastic syndrome. 
Hematol Rep. 2010 Jan 26;2(1):e1. 
Swerdlow SH, Campo E, Harris NL, et. al. WHO Classification of Tumours of Haematopoietic 
and Lymphoid Tissues. Lyon, France: IARC Press; 2008. 
Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets. 2013 
May;17(5):507-31. 
Tipifarnib Investigator’s Brochure, Edition 12, Jan 2015. 
van der Slik AR, Koeleman BP, Verduijn W, et. al.  KIR in type 1 diabetes: disparate distribution 
of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control 
subjects. Diabetes. 2003 Oct;52(10):2639-42. 
Wu J, Lanier LL.  Natural killer cells and cancer. Adv Cancer Res. 2003;90:127-56. 
 
 






Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 74 of 79 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 75 of 79 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 
 
 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 76 of 79 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 77 of 79 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 78 of 79 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 


Tipifarnib  
CTP KO-TIP-003 
 
 
 
 
 
 
 
Page 79 of 79 
 
Protocol Amendment 3, 09 July 2017 
CONFIDENTIAL 
 

SAP_001.pdf: 
Pr ot oc ol  N u m b er:  K O ‐TI P ‐0 0 3  
 
Offici al  Titl e:  A n  A d a pti v e  P h as e  2  St u d y  of  Ti pif ar ni b  i n S u bj ects  wit h  M y el o d ys pl astic  S y n dr o m es  
 
N C T  N u m b er:  N C T 0 2 7 7 9 7 7 7  
 
D oc u m e nt  D at e:  1 9  J ul y 2 0 1 7  


 
S T A TI S TI C A L A N A L Y SI S P L A N  
 
Pr ot oc ol Title:  
A n A da pti ve P hase 2 St u d y of Ti pifar ni b i n S u bjects wit h 
M yel o d ys plastic S y n dr o mes   
 
 
S A P Versi o n:   
1  
 
 
S A P D ate:   
2 3  A pr  2 0 1 8  
 
 
St u d y Dr u g:  
Ti pifar ni b ( R 1 1 5 7 7 7; Zar nestra ™)  
 
 
P h ase of St u d y:    
P hase 2  
 
 
Pr ot oc ol N u m ber:   
K O -TI P -0 0 3  
 
 
Pr ot oc ol Versi o n:  
Pr ot oc ol A me n d me nt 3  
 
 
Pr ot oc ol D ate:  
0 9  J ul y 2 0 1 7  
 
 
S p o ns or:    
K ura O nc ol o g y, I nc.  
3 0 3 3 Scie nce Par k Dri ve,  S uite 2 2 0  
Sa n Die g o , C A 9 2 9 2 1 ( U S A)  
P h o ne: + 1 8 5 8. 5 0 0. 8 8 0 0  
 
C R O Pre p ari n g 
S A P:  
 
 
 
 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
Pa ge 2 of 2 8 
C O N FI D E N TI A L  
SI G N A T U R E P A G E  
T his d oc u me nt has bee n pre pare d, re vie we d a n d a p pr o ve d b y: 
S T U D Y BI O S T A TI S TI CI A N  A P P R O V A L : 
-------------------------------------------------------------------------------------------------------- 
Pri nte d Na me/ Title     
  
  
Si g nat ure  
  
 
Date  
S P O N S O R A P P R O V A L : 
Pri nte d N a me/ Title 
Si g nat ure 
Date  


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 3 of 2 8 
C O N FI D E N TI A L  
 
 
R E VI SI O N S HI S T O R Y L O G  
Versi o n  
Re visi o n 
Date * *  
A ut h or of 
Re visi o n * 
Secti o n(s)  
M o difie d 
Descri pti o n a n d/ or Rea s o n(s) f or 
Re visi o n 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Pr o vi de first i nitial a n d last na me.  
* * U p date t he last re visi o n dates o n t he c o ver pa ge a n d t he hea der. 
 
 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 4 of 2 8 
C O N FI D E N TI A L  
 
 
T A B L E O F C O N T E N T S  
T A B L E O F C O N T E N T S  ................................................................................................................. 4 
1.  
LI S T O F A B B R E VI A TI O N S ....................................................................................... 7  
2.  
I N T R O D U C TI O N ........................................................................................................ 9 
3.  
S T U D Y O BJ E C TI V E S  ................................................................................................ 9 
3. 1.  
Pri mar y O bjecti ve a n d E n d p oi nt .................................................................................. 9  
3. 2.  
Sec o n dar y O bjecti ves a n d E n d p oi nts ........................................................................... 9  
 
 
4.  
S T U D Y D E SI G N  ....................................................................................................... 1 1 
4. 1.  
Ge neral St u d y Desi g n a n d Pla n .................................................................................. 1 1  
4. 2.  
St u d y P o p ulati o n ......................................................................................................... 1 3  
4. 2. 1.  
Selecti o n of St u d y P o p ulati o n .................................................................................... 1 3  
4. 2. 2.  
Re m o val of S u bjects fr o m Treat me nt or Assess me nt  ................................................. 1 3 
4. 3.  
Pre mat ure Disc o nti n uati o n of t he Trial ...................................................................... 1 3  
4. 4.  
Defi niti o n of E n d of St u d y ......................................................................................... 1 3  
4. 5.  
Ra n d o mizati o n a n d Bli n di n g ...................................................................................... 1 3  
4. 6.  
St u d y Assess me nts  ...................................................................................................... 1 4 
5.  
S A M P L E SI Z E D E T E R MI N A TI O N  ......................................................................... 1 8 
6.  
A N A L Y SI S P O P U L A TI O N S  .................................................................................... 1 8 
7.  
G E N E R A L S T A TI S TI C A L C O N SI D E R A TI O N S  .................................................... 1 9 
7. 1.  
I nteri m A nal yses a n d Data M o nit ori n g ...................................................................... 1 9 
7. 2.  
M ulti -Ce nter St u dies  ................................................................................................... 1 9 
7. 3.  
M ulti ple C o m paris o ns / M ulti plicit y  .......................................................................... 2 0 
7. 4.  
E xa mi nati o n of S u b gr o u ps ......................................................................................... 2 0  
7. 5.  
Ha n dli n g of Dr o p o uts or Missi n g Data ...................................................................... 2 0  
7. 6.  
O utlier Ha n dli n g  ......................................................................................................... 2 0 
7. 7.  
A dj ust me nts f or C o variates ........................................................................................ 2 0  
8.  
S U M M A R Y O F S T U D Y P O P U L A TI O N D A T A  ..................................................... 2 0 
8. 1.  
S u bject Dis p ositi o n  ..................................................................................................... 2 0 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 5 of 2 8 
C O N FI D E N TI A L  
 
 
8. 2.  
Pr ot oc ol Vi olati o ns ..................................................................................................... 2 1  
8. 3.  
De m o gra p hics a n d Baseli ne C haracteristics  ............................................................... 2 1 
8. 4.  
D osi n g a n d E xte nt of E x p os ure .................................................................................. 2 1  
8. 5.  
C o nc o mita nt Me dicati o ns  ........................................................................................... 2 1 
8. 6.  
F oll o w U p Assess me nts  .............................................................................................. 2 2 
9.  
E F FI C A C Y A N A L Y S E S  ........................................................................................... 2 2 
9. 1.  
Pri mar y Efficac y A nal yses  ......................................................................................... 2 2 
9. 2.  
Sec o n dar y Efficac y A nal yses  ..................................................................................... 2 2 
9. 3.  
E x pl orat or y Efficac y A nal yses  ................................................................................... 2 3 
1 0.  
S A F E T Y A N A L Y S E S  ............................................................................................... 2 3 
1 0. 1.  
A d verse E ve nts ........................................................................................................... 2 4  
1 0. 2.  
Cli nical La b orat or y E val uati o ns  ................................................................................. 2 5 
1 0. 3.  
Tra nsf usi o n or Gr o wt h Fact or S u p p ort ....................................................................... 2 5  
1 0. 4.  
Vital Si g ns  .................................................................................................................. 2 6 
1 0. 5.  
Ot her Safet y Meas ures  ................................................................................................ 2 6 
1 1.  
C LI NI C A L P H A R M A C O L O G Y A N A L Y S E S  ......................................................... 2 6 
1 2.  
O T H E R A N A L Y S E S  ................................................................................................. 2 6 
1 3.  
D A T A H A N D LI N G C O N V E N TI O N S  ...................................................................... 2 6 
1 4.  
R E P O R TI N G C O N V E N TI O N S ................................................................................ 2 7  
1 5.  
C H A N G E S I N T H E S T A TI S TI C A L M E T H O D S F R O M T H O S E S T A T E D 
I N T H E P R O T O C O L ................................................................................................. 2 7 
1 6.  
R E F E R E N C E S  ........................................................................................................... 2 7 
1 7.  
T A B L E S, FI G U R E S, LI S TI N G S  ............................................................................... 2 8 
 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 6 of 2 8 
C O N FI D E N TI A L  
 
 
LI S T O F T A B L E S  
Ta ble  1: 
A b bre viati o ns ................................................................................................................ 7  
Ta ble  2: 
Sc he d ule of Acti vities ................................................. Err or! B o o k m ar k n ot defi ne d.  
Ta ble  3: 
Perf or ma nce c haracteristics f or sa m ple size deter mi nati o n  ........................................ 1 8 
 
 
 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 7 of 2 8 
C O N FI D E N TI A L  
 
 
1.  
LI S T O F A B B R E VI A TI O N S  
T a ble  1: 
A b bre vi ati o ns  
 
 
A E  
a d verse e ve nt  
A L T  
ala ni ne tra ns mi nase  
A P T T  
acti vate d partial t hr o m b o plasti n ti me  
A Sa T  
all s u bjects as treate d  
A S T  
as partate tra nsa mi nase  
A T C  
a nat o mical t hera pe utic c he mical  
B U N  
bl o o d urea nitr o ge n  
CI  
c o nfi de nce i nter val  
C R  
c o m plete res p o nse  
C S R  
cli nical st u d y re p ort  
C T  
c o m p uter t o m o gra p h y  
C T C A E  
C o m m o n Ter mi n ol o g y Criteria f or A d verse E ve nts  
D O R  
d urati o n of res p o nse  
E C G  
electr ocar di o gra m  
E C O G  
Easter n C o o perati ve O nc ol o g y Gr o u p  Perf or ma nce Stat us  
F A S  
f ull a nal ysis set 
F Tase  
far nes yl tra nsferase 
HI  
he mat ol o gic i m pr o ve me nt  
H L A  
h u ma n le u k oc yte a nti ge n  
I C F 
i nf or me d c o nse nt f or m 
I W G 
I nter nati o nal W or ki n g Gr o u p 
KI R  
Killer -cell i m m u n o gl o b uli n -li ke rece pt ors 
M D S  
m yel o d ys plastic s y n dr o mes  
Me d D R A  
Me dical Dicti o nar y f or Re g ulat or y Acti vities  
N CI  
Nati o nal Ca ncer I nstit ute  
N G S  
ne xt ge nerati o n se q ue nci n g  
O R R  
o bjecti ve res p o nse rate  
P F S  
pr o gressi o n free s ur vi val  
P P  
Per -pr ot oc ol  
P R  
partial res p o nse  
P T  
preferre d ter m  
P T/I N R  
pr ot hr o m bi n ti me / i nter nati o nal n or malize d rati o  
P T C L  
peri p heral T -cell l y m p h o ma  
R B C  
re d bl o o d cell 
S A E  
seri o us a d verse e ve nt 
S A P  
statistical a nal ysis pla n 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
Pa ge 8 of 2 8 
C O N FI D E N TI A L  
S O C  
s yste m or ga n class 
S O P  
sta n dar d o perati n g pr oce d ure 
T E A E  
treat me nt e mer ge nt a d verse e ve nt 
TI  
tra nsf usi o n i n de pe n de nce 
W H O  
W orl d Healt h Or ga nisati o n  






Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 1 1 of 2 8 
C O N FI D E N TI A L  
 
 
4.  
S T U D Y D E SI G N    
4. 1.  
Ge ner al St u d y Desi g n a n d Pl a n  
T his p hase 2 st u d y will i n vesti gate t he a ntit u m or acti vit y i n ter ms of O R R of ti pifar ni b i n 
a ppr o xi matel y 3 6 eli gi ble s u bjects wit h M D S w h o ha ve n o k n o w n c urati ve treat me nt. Eli gi ble 
s u bjects ma y ha ve recei ve d n o m ore t ha n 2 pri or s yste mic re gi me ns. Pri or s yste mic re gi me ns are 
t h ose t hat are c o nsi dere d sta n dar d of care f or t he treat me nt of M D S, ha ve bee n recei ve d at 
sta n dar d d oses f or at least o ne f ull treat me nt c ycle a n d e xcl u de er yt hr o p oiesis-sti m ulati n g a ge nts 
( E S A). 
A t w o -sta ge st u d y desi g n will be e m pl o ye d i n or der t o mi ni mize t he n u m ber of st u d y s u bjects 
treate d if ti pifar ni b were c o nsi dere d n ot s ufficie ntl y efficaci o us t o gra nt f urt her de vel o p me nt i n 
t his s u bject p o p ulati o n. T his desi g n is i nte n de d t o all o w t he ter mi nati o n of accr ual i n case of 
u nacce pta bl y l o w efficac y as meas ure d b y O R R.  
I n t he first sta ge, 2 2 eli gi ble s u bjects will be e nr olle d a n d ra n d o mize d t o 1 of 2 d osi n g re gi me ns 
(re gi me n 1 or re gi me n 2). If t w o or m ore res p o nses are o bser ve d i n a gi ve n d ose re gi me n c o h ort, 
7 a d diti o nal st u d y s u bjects will be e nr olle d.  
S u bjects will be ra n d o mize d t o recei ve ti pifar ni b orall y wit h f o o d, t wice a da y ( bi d) acc or di n g t o 
o ne of t he f oll o wi n g d ose re gi me ns:  
•  Re gi me n 1: 6 0 0 m g bi d f or 7 d a ys o n D a ys 1- 7 i n 2 8 d a y c ycles  (i.e. 1 wee k o n / 3 wee ks 
off).  
At t he discreti o n of t he i n vesti gat or, t he d ose of ti pifar ni b ma y be i ncrease d t o 8 0 0 m g bi d if 
t he s u bject has n ot e x perie nce d d ose li miti n g t o xicities at t he 6 0 0 m g d ose le vel. S u bjects are 
n ot t o be d ose escalate d u ntil after c o m pleti n g C ycle 1 t o e ns ure t he d osi n g re gi me n is 
t olerate d pri or t o escalati o n. Ste p wise 2 0 0 m g d ose re d ucti o ns t o c o ntr ol treat me nt-relate d, 
treat me nt-e mer ge nt t o xicities are als o all o we d. S u bjects w h o de vel o p seri o us a d verse e ve nts 
( S A E), ≥ gra de 2 treat me nt-e mer ge nt a d verse e ve nts ( T E A E) t hat are dee me d relate d t o 
ti pifar ni b a n d lasti n g ≥ 1 4 da ys will n ot u n der g o d ose escalati o n.  
•  Re gi me n 2: 3 0 0 m g bi d f or 2 1 d a ys o n D a ys 1- 2 1 i n 2 8 d a y c ycles (i.e. 3 wee ks o n / 1 
wee k off).  
Ste p wise 1 0 0 m g d ose re d ucti o ns t o c o ntr ol treat me nt- relate d, treat me nt-e mer ge nt t o xicities 
are all o we d. 
S u bjects w h o recei ve d a starti n g d ose of 9 0 0 m g bi d d uri n g t he c o n d uct of t he ori gi nal versi o n of 
t his pr ot oc ol ma y be d ose re d uce d t o t he 6 0 0 m g bi d d ose at t he discreti o n of t he i n vesti gat or 
( pr ot oc ol A me n d me nt 1). S u bjects w h o recei ve d ti pifar ni b o n Da ys 1 – 7 a n d Da ys 1 5 – 2 1 
d uri n g t he c o n d uct of t he ori gi nal versi o n a n d a me n d me nt 1 of t his pr ot oc ol, ma y tra nsiti o n t o 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 1 2 of 2 8 
C O N FI D E N TI A L  
 
 
t he ne w treat me nt a d mi nistrati o n sc he d ule (ti pifar ni b o n Da ys 1- 7 i n 2 8 da y c ycles) be gi n ni n g o n 
Da y 1 of t heir ne xt c ycle. 
S u bjects accr ue d pri or t o Pr ot oc ol A me n d me nt 3, 0 9 J ul y 2 0 1 7, will n ot be i ncl u de d i n t he t otal 
dis p ositi o n a n d were n ot c o nsi dere d i n t he sta m ple size deter mi nati o n detaile d i n secti o n 5 of t his 
S A P.  T he esti mate d n u m ber of 3 6 s u bjects e nr olle d d o n ot i ncl u de t hese s u bjects.  F or a nal ysis, 
t his s u bject p o pulati o n will o nl y be i ncl u de d i n t he T otal A d verse E ve nt ta bles. 
I n t he a bse nce of u n ma na gea ble t o xicities, s u bjects ma y c o nti n ue t o recei ve ti pifar ni b treat me nt 
u ntil disease pr o gressi o n. If a c o m plete res p o nse ( C R) is o bser ve d, t hera p y wit h ti pifar ni b will be 
mai ntai ne d f or at least 6 m o nt hs be y o n d t he start of res p o nse.  
He mat ol o gic assess me nts, i ncl u di n g peri p heral bl o o d e val uati o ns a n d re vie w of tra nsf usi o n 
re q uire me nts, will be perf or me d at scree ni n g a n d at least m o nt hl y u ntil disease pr o gressi o n. 
Dis ease assess me nts will als o be perf or me d at scree ni n g a n d at least o nce e ver y a p pr o xi matel y 
1 2 wee ks starti n g at t he e n d of c ycle 3. As part of t he disease assess me nt at scree ni n g a n d d uri n g 
C ycles 3, 6 a n d 9, b o ne marr o w e val uati o n will be perf or me d. T here after, b o ne marr o w 
e val uati o ns will occ ur d uri n g disease assess me nts i n acc or da nce wit h i nstit uti o nal sta n dar d 
practice. A d diti o nal he mat ol o gic or disease assess me nts ma y be c o n d ucte d if dee me d necessar y 
b y t he I n vesti gat or. T he ti mi n g of t he he mat ol o gic a n d disease assess me nts s h o ul d be mai ntai ne d 
as m uc h as p ossi ble i n de pe n de ntl y of p ote ntial treat me nt c ycle dela ys.  
Deter mi nati o n of O R R will be assesse d b y t he I n vesti gat or acc or di n g t o t he M D S I nter nati o nal 
W or ki n g Gr o u p (I W G) criteria  (Ta ble 8  a n d Ta ble 9 i n t he st u d y pr ot oc ol ). 
U p o n disease pr o gressi o n, all s u bjects i n t he st u d y will be f oll o we d a p pr o xi matel y e ver y 1 2 
wee ks f or s ur vi val a n d t he use of s u bse q ue nt t hera p y u ntil eit her deat h or 1 2 m o nt hs after accr ual 
of t he st u d y has bee n c o m plete d, w hic he ver occ urs first. I nf or mati o n o n s ur vi val a n d s u bse q ue nt 
a ntica ncer t hera p y ma y be c ollecte d b y p h o ne. 
S u bjects w h o ter mi nate treat me nt f or reas o ns ot her t ha n deat h or disease pr o gressi o n will be 
assesse d at re g ular i nter vals f or disease pr o gressi o n (a p pr o xi matel y e ver y 1 2 wee ks) a n d 
le u ke mic tra nsf or mati o n ( m o nt hl y bl o o d c o u nts). Disease assess me nts perf or me d d uri n g t he first 
9 m o nt hs fr o m t he start of t he s u bject’s partici pati o n i n t he st u d y will i ncl u de b o ne marr o w 
e val uati o n. T hereafter, b o ne marr o w e va l uati o ns will occ ur d uri n g disease assess me nts i n 
acc or da nce wit h i nstit uti o nal sta n dar d practice. T hese assess me nts will c o nti n ue u ntil disease 
pr o gressi o n, wit h dra wal of s u bject’s c o nse nt t o st u d y pr oce d ures or i nitiati o n of a n ot her 
a ntica ncer t hera p y.  
A ll s u bjects will be f oll o we d- u p f or safet y d uri n g treat me nt a n d u p t o a p pr o xi matel y 3 0 da ys ( 3 0 
± 7 da ys) after treat me nt disc o nti n uati o n or u ntil i m me diatel y bef ore t he i nitiati o n of a n ot her 
a ntica ncer t hera p y, w hic he ver occ urs first. A d diti o nal f oll o w u p ma y be i m ple me nte d u ntil t he 
s u bject rec o vers fr o m a n y e mer ge nt treat me nt relate d t o xicit y or t he a d verse e ve nt is c o nsi dere d 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 1 3 of 2 8 
C O N FI D E N TI A L  
 
 
irre versi ble b y t he I n vesti gat or. Tar get or ga n t o xicities will be m o nit ore d via cli nical a n d 
la b orat or y assess me nts usi n g t he N CI C T C A E v . 4. 0 3 criteria.  
4. 2.  
St u d y P o p ul ati o n  
4. 2. 1.  
Selecti o n of St u d y P o p ul ati o n  
A p pr o xi matel y 3 6 male a n d fe male s u bjects  wit h M D S w h o are at least 1 8 years ol d  a n d w h o 
meet t he i ncl usi o n a n d e xcl usi o n criteria as o utli ne d i n Pr ot oc ol Secti o n 7 will be e nr olle d i n t he 
st u d y.  
4. 2. 2.  
Re m o v al of S u bjects fr o m Tre at me nt or Assess me nt  
S u bjects ma y wit h dra w t heir c o nse nt t o partici pate i n t his st u d y at a n y ti me wit h o ut prej u dice. 
T he I n vesti gat or m ust wit h dra w fr o m t he st u d y a n y s u bject w h o re q uests t o be wit h dra w n. A 
s u bject’s partici pati o n i n t he st u d y ma y als o be disc o nti n ue d at a n y ti me at t he discreti o n of t he 
I n vesti gat or a n d i n acc or da nce wit h his/ her cli nical j u d g me nt. E ver y eff ort s h o ul d be ma de t o 
c o m plete, w he ne ver p ossi ble, t he tests a n d e val uati o ns liste d f or t he E n d of Treat me nt visit. T he 
S p o ns or als o reser ves t he ri g ht t o disc o nti n ue t he st u d y at a n y ti me f or eit her cli nical researc h or 
a d mi nistrati ve reas o ns a n d t o disc o nti n ue partici pati o n b y a n i n di vi d ual I n vesti gat or or site f or p o or 
e nr oll me nt or n o nc o m plia nce.  M ore details are a vaila ble i n Pr ot oc ol Secti o n 8. 4.  
4. 3.  
Pre m at ure Disc o nti n u ati o n of t he Tri al  
T his trial ma y be disc o nti n ue d pre mat urel y i n t he e ve nt of a n y of t he reas o ns liste d i n Pr ot oc ol 
Secti o n 8. 5. 
4. 4.  
Defi niti o n of E n d of St u d y  
F or a d mi nistrati ve a n d safet y re p orti n g p ur p oses, t he e n d of t his cli nical st u d y is defi ne d as 1 2 
m o nt hs fr o m e nr oll me nt of t he last e nr olle d st u d y s u bject. If t he last e nr olle d st u d y s u bject 
disc o nti n ues treat me nt wit hi n 1 2 m o nt hs of st u d y e nr oll me nt, t he E n d of St u d y will occ ur n o 
earlier t ha n t he date of t he last e nr olle d s u bject’s safet y f oll o w -u p assess me nt perf or me d 
a p pr o xi matel y 3 0 da ys after treat me nt disc o nti n uati o n ( or u ntil i nitiati o n of a n ot her a nti -ca ncer 
t hera p y). At t he ti me of E n d of St u d y, pr o visi o ns will be ma de t o tra nsiti o n all re mai ni n g st u d y 
s u bjects w h o de m o nstrate s ustai ne d cli nical be nefit be y o n d t he e n d of t he st u d y t o ot her mea ns 
of c o nti n ue d treat me nt wit h a p pr o priate safet y m o nit ori n g, e. g. si n gle patie nt treat me nt pr ot oc ol. 
4. 5.  
R a n d o miz ati o n a n d Bli n di n g  
I n t he first sta ge, 2 2 eli gi ble s u bjects will be e nr olle d a n d ra n d o mize d i n t o o ne of t w o d ose 
re gi me n c o h orts ( 1 1 s u bjects per c o h ort).  T he S p o ns or will be dele gati n g t he ra n d o mizati o n of 
s u bjects a n d a n y ass ociati n g d oc u me ntati o n.   
T his is a n o pe n la bel st u d y wit h n o place b o or c o m parat ors. 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 1 4 of 2 8 
C O N FI D E N TI A L  
 
 
4. 6.  
St u d y Assess me nts  
Details of sc he d ule d assess me nts are dis pla ye d i n  Ta ble 2.  
 








Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 1 8 of 2 8 
C O N FI D E N TI A L  
 
 
5.  
S A M P L E SI Z E D E T E R MI N A T I O N 
A t w o -sta ge st u d y desi g n was selecte d i n or der t o mi ni mize t he n u m ber of stu d y s u bjects treate d 
if ti pifar ni b were c o nsi dere d n ot s ufficie ntl y efficaci o us t o gra nt f urt her de vel o p me nt i n t his 
s u bject p o p ulati o n. T his desi g n is i nte n de d t o all o w t he ter mi nati o n of accr ual i n case of 
u nacce pta bl y l o w efficac y as meas ure d b y O R R a n d  will be e val uate d i n a F A S basis.  
I n t he first sta ge, 2 2 eli gi ble s u bjects will be e nr olle d a n d ra n d o mize d i n t o o ne of t w o d ose 
re gi me n c o h orts ( 1 1 s u bjects per c o h ort). If t w o or m ore res p o nses are o bser ve d i n a gi ve n d ose 
re gi me n c o h ort, 7 a d diti o nal st u d y s u bjects will be e nr olle d. Eac h d ose re gi me n c o h ort is 
desi g ne d t o test t he n ull h y p ot hesis of O R R rate less t ha n 1 0 % vs alter nati ve h y p ot hesis of O R R 
rate at least 3 0 % a n d will be e val uate d i n de pe n de ntl y. At t he c o m pleti o n of t he st u d y, treat me nt 
wil l be c o nsi dere d of f urt her i nterest if 4 or m ore s u bjects i n t he 1 8 s u bject d ose re gi me n c o h ort 
ac hie ve a res p o nse, i.e. t he tr ue O R R is hi g her t ha n 1 0 %. 
T o deter mi ne t he t otal trial size, a res p o nse of i nterest of 3 0 % is ass u me d. T his desi g n pr o vi des 
8 0 % p o wer t o detect a differe nce bet wee n 1 0 % a n d 3 0 % re d bl o o d cell (R B C ) tra nsf usi o n 
i n de pe n de nce (TI ) rate at o ne-si de d si g nifica nce le vel of 0. 0 8 7. Usi n g t his desi g n, t he pr o ba bilit y 
of ter mi nati n g eac h strat u m at t he e n d of sta ge 1 if t he tr ue rate is 1 0 % is 0. 6 9 7 w hile t he 
pr o ba bilit y of ter mi nati n g eac h strat u m at t he e n d of sta ge 1 if t he tr ue rate is 3 0 % is 0. 1 1 3.   
T he perf or ma nce c haracteristics of t his a p pr oac h are s h o w n i n Ta ble 3. 
T a ble  2: 
Perf or m a nce c h ar acteristics f or s a m ple size deter mi n ati o n  
 
 
Pr o b a bili t y to c o ncl u de  TR U E  rat e > 0. 1 0 if T R U E  u n d erly i n g 
R B C  T I resp o n se rat e is a s i n dicat e d 
T R U E  R at e -->  
0. 1  
0. 3  
0. 4  
N = 1 1  
0. 0 9  
0. 6 9  
0. 8 8  
N = 1 8  
0. 1  
0. 8 3  
0. 9 7  
N = 2 5  
0. 1  
0. 9 1  
0. 9 9  
N = 3 2  
0. 0 9  
0. 9 5  
> 0. 9 9  
6.  
A N A L Y SI S  P O P U L A TI O N S  
F ull A nal ysis S et ( F A S) 
T he f ull a nal ysis set ( F A S) will ser ve as t he pri mar y p o p ulati o n f or t he a nal ysis of O R R a n d 
ot her efficac y -relate d data. Pri or t o Pr ot oc ol A me n d me nt 3 ( versi o n 0 9 J ul 2 0 1 7), ot her s u bjects 
were e nr olle d i nt o t he trial usi n g a differe nt d ose re gi me n. Als o, f or i ncl usi o n i n t he F A S, 
s u bjects m ust meet all Pr ot oc ol A me n d me nt 3 i ncl usi o n criteria. F or t he p ur p oses of t he pri mar y 
a nal ysis (a d va nce me nt fr o m sta ge 1 t o sta ge 2 a n d o verall a nal ysis f or eac h d ose re gi me n 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 1 9 of 2 8 
C O N FI D E N TI A L  
 
 
c o h ort), t h ose s u bjects will n ot be i ncl u de d. T he e xcl u de d s u bject data will be s u m marize d 
se paratel y i n t he re p orti n g of t he st u d y. 
T heref ore, s u bjects will be e xcl u de d f or F A S f or t he f oll o wi n g reas o ns:  
•  Di d n ot meet eli gi bilit y criteria as o utli ne d i n Pr ot oc ol A me n d me nt 3 ( versi o n 0 9 J ul 
2 0 1 7)  
•  Fail ure t o recei ve at least o ne d ose of ti pifar ni b  
•  N o p ost- baseli ne e n d p oi nt data s u bse q ue nt t o at least 1 d ose of st u d y dr u g. 
•  E nr olle d pri or t o Pr ot oc ol A me n d me nt 3 ( versi o n 0 9 J ul 2 0 1 7) 
 
Per - Pr ot oc ol ( P P) P o p ulati o n 
A s u p p orti ve a nal ysis ma y be perf or me d o n t he P P  p o p ulati o n w hic h e xcl u des s u bjects d ue t o 
i m p orta nt de viati o ns fr o m t he pr ot oc ol t hat ma y s u bsta ntiall y affect t he res ults of t he pri mar y 
a nal ysis, s uc h as n ot ta ki n g at least 8 0 % of t he i nte n de d d ose i n c ycle 1. T he fi nal deter mi nati o n 
o n pr ot oc ol vi olati o ns, a n d t here b y t he c o m p ositi o n of t he P P  p o p ulati o n, will be ma de pri or t o 
l oc ki n g t he cli nical data base a n d fi nal a nal ysis a n d will be d oc u me nte d i n a se parate 
me m ora n d u m. 
All S u bjects as Treate d ( A Sa T) P o p ulati o n 
T he A Sa T p o p ulati o n will be use d f or t he a nal ysis of safet y data. T he A Sa T p o p ulati o n c o nsists 
of all e nr olle d s u bjects w h o recei ve at least o ne d ose of ti pifar ni b. At least o ne la b orat or y or vital 
si g n meas ure me nt o btai ne d s u bse q ue nt t o at least o ne d ose of st u d y dr u g is re q uire d f or i ncl usi o n 
i n t he a nal ysis of a s pecific safet y para meter. T o assess c ha n ge fr o m baseli ne, a baseli ne 
meas ure me nt is als o re q uire d .  
7.  
G E N E R A L S T A TI S TI C A L C O N SI D E R A TI O N S  
7. 1.  
I nteri m A n al yses a n d D at a M o nit ori n g 
Base d o n t he t w o-sta ge trial desi g n, a n i nteri m a nal ysis will be c o n d ucte d t o deter mi ne 
a d va nce me nt fr o m Sta ge 1 t o Sta ge 2. S pecificall y, acc or di n g t o t he Pr ot oc ol, Secti o n 8. 1, if 2 
res p o nses are o bser ve d d uri n g Sta ge 1, t he n 7 a d diti o nal s u bjects will be e nr olle d i n Sta ge 2. If 
0- 1 o bjecti ve res p o nses are o bser ve d, t he st u d y will be c l ose d t o f urt her ree nr oll me nt. N o 
statistical h y p ot hesis will be teste d f or t his a nal ysis. 
7. 2.  
M ulti -Ce nter St u dies  
T his is a m ulti -ce nter st u d y. Gi ve n t he s mall sa m ple size of t he st u d y, n o  site effect will be 
c o nsi dere d i n a n y statistical a nal ysis.    


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 2 0 of 2 8 
C O N FI D E N TI A L  
 
 
7. 3.  
M ulti ple C o m p aris o ns / M ulti plicit y  
Gi ve n t he s mall sa m ple size, n o a dj ust me nt f or m ulti ple c o m paris o ns/ m ulti plicit y will be 
perf or me d. T heref ore, o nl y n o mi nal p- val ues will be re p orte d.  
7. 4.  
E x a mi n ati o n of S u b gr o u ps  
N o s u b- gr o u p a nal yses are pla n ne d. 
7. 5.  
H a n dli n g of Dr o p o uts or Missi n g D at a  
W here i n di vi d ual data p oi nts are missi n g beca use of i ns ufficie nt sa m ples, dr o p o uts, or ot her 
reas o ns, t he data will be a nal yze d base d o n re d uce d de n o mi nat ors. F or s ur vi val a nal ysis, 
dr o p o uts wit h o ut c o nfir mi n g e ve nts will be treate d as ce ns ore d. 
7. 6.  
O utlier H a n dli n g  
P ote ntial data e ntr y err ors ma nifeste d as o utliers will be ha n dle d i n t he data ma na ge me nt pr ocess 
t hr o u g h e dit c hec ks. 
7. 7.  
A dj ust me nts  f or Co v ari ates  
N ot a p plica ble.  
8.  
S U M M A R Y O F S T U D Y P O P U L A TI O N D A T A   
U nless s pecificall y n ote d, all ta bles, listi n gs, a n d fi g ures descri be d will n ot i ncl u de s u bjects 
e nr olle d pri or t o Pr ot oc ol A me n d me nt 3. 
8. 1.  
S u bject Dis p ositi o n  
S u bject dis p ositi o n will be pr o vi de d f or all s u bjects scree ne d. A s u m mar y ta ble will prese nt t he 
t otal n u m ber of s u bjects scree ne d, t otal n u m ber of scree n fail ures, a n d t otal n u m ber w h o recei ve d 
a n y st u d y dr u g.  A m o n g s u bjects w h o recei ve d a n y st u d y dr u g, t his s u m mar y will als o prese nt 
t he fre q ue nc y a n d perce nta ge of s u bjects w h o c o m plete d treat me nt, a n d w h o disc o nti n ue d 
treat me nt.  T he pri mar y reas o ns f or disc o nti n uati o n of treat me nt, a n d f or e n d of st u d y will be 
ta b ulate d. 
Detaile d s u bject dis p ositi o n i nf or mati o n, as well as eli gi bilit y a n d a nal ysis p o p ulati o n 
assi g n me nt will pr o vi de d i n listi n gs.  


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 2 1 of 2 8 
C O N FI D E N TI A L  
 
 
8. 2.  
P r ot oc ol Vi ol ati o ns  
T he fre q ue nc y a n d perce nta ge of s u bjects disc o nti n ue d d ue t o pr ot oc ol vi olati o n will be 
s u m marize d i n t he dis p ositi o n ta ble descri be d a b o ve. 
Pr ot oc ol vi olati o ns res ulti n g i n earl y ter mi na ti o n of s u bjects will be prese nte d i n t he dis p ositi o n 
listi n g.  
8. 3.  
De m o gr a p hics a n d B aseli ne C h ar acteristics  
Descri pti ve statistics of de m o gra p hic meas ure me nts at scree ni n g s uc h as a ge, se x, et h nicit y, race , 
meas ure me nts of hei g ht  a n d wei g ht, n u m ber of pri or tra nsf usi o ns, a n d Easter n C o o perati ve 
O nc ol o g y Gr o u p  Perf or ma nce Stat us ( E C O G ) perf or ma nce stat us sc ore at Scree ni n g will be 
s u m marize d f or t he A Sa T P o p ulati o n  a n d f or t he F A S p o p ulati o n..  
Me dical a n d s ur gical hist or y / p h ysical fi n di n gs will be c o de d usi n g latest Me dical Dicti o nar y f or 
Re g ulat or y Acti vities ( Me d D R A) versi o n a n d s u m marize d b y s yste m or ga n class ( S O C)/  
preferre d ter m ( P T)  f or t he A Sa T P o p ulati o n.   
A s u m mar y of M D S dia g n osis at sree ni n g will be pr o vi de d f or t he A Sa T p o p ulati o n. 
T he res p o nse t o pre vi o us a nti-ca ncer t hera pies will be s u m marize d f or b ot h t he A Sa T p o p ulati o n, 
a n d t he F A S p o p ulati o n. 
Data f or de m o gra p hics a n d baseli ne c haracteristics will be prese nte d i n listi n gs. 
8. 4.  
D osi n g a n d E xte nt of E x p os ure  
A vera ge c o m plia nce will be calc ulate d f or eac h s u bject as t he a vera ge o ver all dail y re p orte d 
val ues of (act ual d ose / pla n ne d d ose) × 1 0 0 %. 
N u m ber of treat me nt c ycles a n d a vera ge c o m plia nce will be s u m marize d  usi n g descri pti ve 
statistics. Fre q ue nc y a n d perce nta ge of s u bjects w h o e x perie nce d t otal i nci de nces of dr u g 
m o dificati o n ( d ose re d ucti o n, d ose i nterr u pti o n , d ose i ncrease, or dr u g wit h dra w n) will be 
s u m marize d.   
Data f or st u d y dr u g dis pe nsi n g a n d d osi n g will be prese nte d i n listi n gs. 
8. 5.  
C o nc o mit a nt Me dic ati o ns  
Pri or ca ncer t hera pies, a n d pri or a n d c o nc o mita nt me dicati o ns ( ot her t ha n ca ncer treat me nt) will 
be c o de d b y W H O Dr u g Dicti o nar y ( versi o n Dece m ber 2 0 1 6) a n d s u m marize d b y preferre d 
A T C 3 ter ms a n d preferre d ter ms .   
Data f or pri or pri or ca ncer t hera pies a n d f or p ri or a n d c o nc o mita nt me dicati o n ( ot her t ha n ca ncer 
treat me nt) will be prese nte d i n listi n gs.   


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 2 2 of 2 8 
C O N FI D E N TI A L  
 
 
8. 6.  
F oll o w U p Assess me nts  
T he dates of p ost treat me nt f oll o w u p assess me nts f or s u bse q ue nt t hera p y a n d f or s ur vi val will 
be prese nte d i n listi n gs.  
9.  
E F FI C A C Y A N A L Y S E S    
T he efficac y of ti pifar ni b will be assesse d base d o n t he f oll o wi n g e n d p oi nts: 
•  Res p o nse assess me nts acc or di n g t o t he M D S I W G criteria ( Ta ble 8  a n d Ta ble 9  i n t he st u d y 
pr ot oc ol).  
•  Tra nsf usi o n re q uire me nts d uri n g t he st u d y peri o d. 
9. 1.  
Pri m ar y Effic ac y A n al yses  
T he o bjecti ve res p o nse rate will be esti mate d a n d i ncl u des t he f oll o wi n g res p o nse t y pes   C R, P R, 
marr o w C R a n d HI  acc or di n g t o t he M D S I W G criteria ( Ta ble 8  a n d Ta ble 9  i n t he st u d y 
pr ot oc ol).   T he esti mate of t he O R R  will be calc ulate d base d o n t he ma xi m u m li keli h o o d 
esti mat or (i.e., cr u de pr o p orti o n of s u bjects w h ose best o verall res p o nse is C R, P R, marr o w C R 
or HI). T he esti mate of t he O R R  will be acc o m pa nie d b y a 2-si de d 9 5 % e xact bi n o mial 
c o nfi de nce i nter val. 
9. 2.  
Sec o n d ar y Effic ac y A n al yses  
Tra nsf usi o n i n de pe n de nce a n d disease res p o nse will be s u m marize d descri pti vel y per d ose 
re gi me n c o h ort a n d o verall. 
T he d urati o n of o bjecti ve res p o nse will be calc ulate d f or s u bjects w h o ac hie ve C R, P R, marr o w 
C R or HI. F or s uc h s u bjects, t he d urati o n of o bjecti ve res p o nse is defi ne d as t he n u m ber of da ys 
fr o m t he start date of res p o nse ( w hic he ver res p o nse is ac hie ve d first) t o t he first date t hat 
pr o gressi ve disease ( P D) is o bjecti vel y d oc u me nte d. Disease pr o gressi o n will be deter mi ne d b y 
t he I n vesti gat or usi n g M D S I W G criteria (Ta ble 9  i n t he st u d y pr ot oc ol). T he D O R  will be ri g ht -
ce ns ore d f or s u bjects w h o ac hie ve a res p o nse a n d meet 1 of t he f oll o wi n g c o n diti o ns: 
1)  N o n- pr ot oc ol a ntica ncer treat me nt starte d bef ore d oc u me ntati o n of dise ase pr o gressi o n;  
2)  D eat h or d oc u me nte d disease pr o gressi o n after m ore t ha n 1 misse d disease assess me nt visit;  
3)  Ali ve a n d d oes n ot ha ve d oc u me ntati o n of disease pr o gressi o n bef ore a data a nal ysis c ut off 
date.  
T he D O R  will be s u m marize d descri pti vel y usi n g t he  Ka pla n - Meier met h o d. T he 5 0t h perce ntile 
of t he Ka pla n- Meier distri b uti o n will be use d t o esti mate t he me dia n res p o nse d urati o n. 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 2 3 of 2 8 
C O N FI D E N TI A L  
 
 
P F S  will be defi ne d as t he ti me (i n m o nt hs) fr o m e nr oll me nt t o eit her first o bser vati o n of 
pr o gressi ve disease or occ urre nce o f deat h d ue t o a n y ca use wit hi n 1 year (a p pr o xi matel y 4 ti me 
i nter vals f or disease assess me nts) of eit her first a d mi nistrati o n of ti pifar ni b or t he last disease 
assess me nt. Si milarl y, s ur vi val will be defi ne d as t he ti me (i n m o nt hs) fr o m e nr oll me nt t o 
occ u rre nce of deat h d ue t o a n y ca use wit hi n 1 year (a p pr o xi matel y 4 ti me i nter vals f or disease 
assess me nts) of eit her first a d mi nistrati o n of ti pifar ni b or t he last disease assess me nt.  
Deter mi nati o n of R B C tra nsf usi o n i n de pe n de nce will be assesse d b y t he I n vesti gat or t hr o u g h t he 
re vie w of s u bject tra nsf usi o n re q uire me nts a n d he m o gl o bi n le vels.  R B C TI  will be defi ne d as 
t he a bse nce of t he i ntra ve n o us i nf usi o n of a n y R B C tra nsf usi o n d uri n g a n y c o nsec uti ve “r olli n g” 
5 6 da ys d uri n g t he treat me nt peri o d, i.e. da ys  1 t o 5 6, da ys 2 t o 5 7, da ys 3 t o 5 8, etc. a n d a ≥ 1 
g/ d L i ncrease i n he m o gl o bi n le vel.  T he rise i n t he he m o gl o bi n c o nce ntrati o n i n s u bjects w h o n o 
l o n ger re q uire tra nsf usi o ns will be calc ulate d as t he differe nce bet wee n t he ma xi m u m 
he m o gl o bi n c o nce ntrati o n a n d t he mi ni m u m pre-tra nsf usi o n val ue d uri n g t he 1 2 wee ks bef ore 
e nr oll me nt i n t he st u d y. 
9. 3.  
E x pl or at or y Effic ac y A n al yses  
Bi o mar ker a nal ysis will be ma na ge d a n d a nal yze d b y K ura O nc ol o g y, I nc a n d will n ot be a part 
of t his statistical a nal ysis pla n.  Deta ils will be descri be d else w here. 
1 0.  
S A F E T Y A N A L Y S E S  
Safet y a n d t olera bilit y of ti pifar ni b will be assesse d base d o n t he f oll o wi n g:  
•  I nci de nce, d urati o n a n d se verit y of T E A Es , S A Es , A Es  res ulti n g i n per ma ne nt 
disc o nti n uati o n of st u d y dr u g, a n d deat hs wit hi n a p pr o xi matel y 3 0 da ys fr o m t he last 
d ose of st u d y dr u g ( or i m me diatel y bef ore t he a d mi nistrati o n of a n ot her a nti- ca ncer 
treat me nt)  
•  C ha n ges i n la b orat or y test res ults  
•  Ser u m C he mistr y: Bl o o d Urea Nitr o ge n, Creati ni ne,  P otassi u m, Calci u m,   T otal 
Bilir u bi n,  A L T, A S T  
•  He mat ol o g y: W hite Bl o o d Cell C o u nt, He m o gl o bi n, Platelet C o u nt, A bs ol ute 
Ne utr o p hil C o u nt,  Ne utr o p hil Prec urs or s  ( pr o m yel oc ytes, m yel oc ytes, 
meta m yel oc ytes, ba n d ne utr o p hils) , L y m p h oc ytes, M o n oc ytes,  Blasts, a n d 
R etic ul oc ytes . 
•  C oa g ulati o n pa nel: P T/I N R, A P T T    
•  C ha n ges i n vital si g ns : bl o o d press ure, heart rate, te m perat ure  


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 2 4 of 2 8 
C O N FI D E N TI A L  
 
 
U nless e x plicitl y i n dicate d ot her wise, all a nal yses f or safet y will be base d o n t he A Sa T 
p o p ulati o n. 
1 0. 1.  
A d verse E ve nts  
A d verse e ve nts will be c o de d usi n g t he latest a vaila ble versi o n of t he Me dical Dicti o nar y f or 
Re g ulat or y Acti vities ( Me d D R A). Treat me nt -e mer ge nt a d verse e ve nts are defi ne d as A Es  t hat 
start o n or after t he first d ose of st u d y dr u g a n d wit hi n a p pr o xi matel y 3 0 da ys of t he last 
a d mi nistrati o n of st u d y dr u g. A Es  will be s u m marize d b y t he n u m ber a n d perce nta ge of s u bjects 
w h o e x perie nce d t he e ve nt, acc or di n g t o S O C  a n d P T . A s u bject re p orti n g m ulti ple cases of t he 
sa me A E  will be c o u nte d o nce wit hi n eac h S O C  a n d si milarl y c o u nte d o nce wit hi n eac h P T . F or 
s u m maries b y ma xi m u m se verit y, eac h s u bject will be c o u nte d o nl y o nce u n der t he m ost se vere 
e ve nt.  
U nless s pecifie d ot her wise, t he de n o mi nat or f or t hese calc ulati o ns will be base d o n t he n u m ber 
of s u bjects w h o recei ve d at leas t o ne a d mi nistrati o n of ti pifar ni b re gar dless of t he t otal n u m ber 
of d oses or treat me nt c ycles a d mi nistere d. T hese c o n ve nti o ns will be a p pr o priatel y m o difie d t o 
calc ulate A E i nci de nce rates se paratel y f or eac h c ycle t hat st u d y t hera p y is a d mi nistere d. A E 
inci de nce rates ma y als o be calc ulate d base d o n ot her meas ures of s u bject e x p os ure (e. g., t otal 
n u m ber of treat me nt c ycles a d mi nistere d). F or s u bjects e nr olle d pri or t o Pr ot oc ol A me n d me nt 3, 
t heir A E c o u nts will o nl y be pr o vi de d i n t he T otal c ol u m n ( Re gi me n 1 + Re gi me n 2 + Ori gi nal 
C o h ort).  Re gi me n 1 a n d Re gi me n 2 s u bjects will be prese nte d se paratel y a n d i n t he T otal 
c ol u m ns. 
A E d urati o ns will be calc ulate d usi n g all T E A Es. F or a n y A E t hat is still o n g oi n g at t he e n d of 
st u d y, we will use t he last c o ntact date as t he e n d of A E st o p date f or calc ulati o n t he d urati o n of 
A Es.  Me dia n, mi ni m u m a n d ma xi m u m of A E d urati o ns will be re p orte d. 
A Es will als o be s u m marize d b y N CI- C T C A E versi o n 4. 0 3 se verit y gra de a n d b y relati o ns hi p t o 
eac h st u d y dr u g. A d diti o nal s u m maries ma y als o be pr o vi de d f or S A Es, a n d e ve nts res ulti n g i n 
t he per ma ne nt disc o nti n uati o n of t hera p y. All A Es will be i ncl u de d i n i n di vi d ual s u bject listi n gs. 
He mat ol o gic a b n or malities re p orte d as A Es t hat were c o de d t o preferre d ter ms i n t he 
I n vesti gati o ns S O C ha ve bee n p o ole d wit h a p pr o priate ter ms i n t he Bl o o d a n d L y m p hatic 
S yste m S O C f or ta b ulati o n f or t he f oll o wi n g cate g ories: 
•  Platelet c o u nt decrease d = T hr o m b oc yt o pe nia;  
•  Ne utr o p hil c o u nt decrease d = Ne utr o pe nia;  
•  W hite bl o o d cell c o u nt decrease d = Le u k o pe nia;  
•  L y m p h oc yte c o u nt decrease d = L y m p h o pe nia. 
 


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 2 5 of 2 8 
C O N FI D E N TI A L  
 
 
O verall vie w of T E A Es will be pr o vi de d, w hic h will i ncl u de t he t otal n u m ber of T E A Es, 
fre q ue nc y of s u bjects wit h T E A Es, dr u g-relate d A Es, S A Es, dr u g-relate d S A Es, or deat h wit hi n 
3 0- da ys wit hi n a d mi nistrati o n of st u d y- dr u g; a n d A Es lea di n g t o per ma ne nt disc o nti n uati o n of 
st u d y dr u g. A d diti o nall y, a c orres p o n di n g  o verall vie w of e x p os ure-a dj uste d A E i nci de nce will 
be pr o vi de d, i n w hic h t he e x p os ure- a dj uste d i nci de nce rate, is calc ulate d as t he mea n n u m be r of 
e ve nts per treat me nt c ycle, wit h c orres p o n di n g 9 5 % c o nfi de nce i nter vals. 
S u m mar y ta bles will be pr o vi de d w hic h prese nt t he i nci de nce of T E A Es b y S O C a n d P T; a n d t he 
i nci de nce of T E A Es b y S O C/ P T b y ma xi m u m se verit y ( N CI- C T C A E Gra des 1 t hr o u g h 5).  
S u m m ar y ta bles will be pr o vi de d w hic h prese nt t he i nci de nce of he mat ol o g y-relate d T E A Es b y 
S O C a n d P T ; a n d t he i nci de nce of he mat ol o g y-relate d T E A Es b y S O C/ P T b y ma xi m u m t o xicit y 
gra de.  
A s u m mar y of t he A E d urati o ns f or all T E A Es b y S O C/ P T will be pr o vi de d.  
S u m mar y ta bles will be pr o vi de d w hic h prese nt t he i nci de nce of st u d y- dr u g relate d T E A Es ; a n d 
t he i nci de nce of st u d y-dr u g relate d T E A Es se verit y sc ores of Gra de  3 or hi g her.   
S u m mar y ta bles will be pr o vi de d w hic h prese nt t he i nci de nce  of S A Es b y S O C/ P T; a n d t he 
i nci de nce of T E A Es lea di n g t o per ma ne nt disc o nti n uati o n of dr u g b y S O C/ P T.  
Data o n  A Es  will be prese nte d i n listi n gs . 
1 0. 2.  
Cli nic al L a b or at or y E v al u ati o ns   
H e mat ol o gical t o xicities Gra de  3 or a b o ve base d o n N CI- C T C A E versi o n 4. 0 3 criteria wi ll be 
s u m marize d acr oss all treat me nt c ycles. A s hift ta ble will be prese nte d f or t he s hift fr o m baseli ne 
t o w orst p ost-baseli ne se verit y gra de.  Se verit y gra di n g is base d o n t he Nati o nal Ca ncer I nstit ute 
C o m m o n Ter mi n ol o g y Criteria f or A d verse E ve nts ( C T C A E), versi o n 4. 0 3, wit h n or mal ra n ges 
defi ne d fr o m t he A merica n M e dical A ss ociati o n Sta n dar d La b N or mal Ra n ges.  F or la b orat or y 
val ues t hat fall o utsi de t he defi ne d se verit y ra n ges, a val ue of 0 was e ntere d.   N ot A p plica ble is 
gi ve n t o t h ose la b orat or y val ues t hat ha ve n o ass ociate d C T C A E se verit y criteria.  
T he data f or cli nical la b orat or y e val uati o ns (i ncl u di n g he mat ol o g y, c he mistr y, c oa g ulati o n, a n d 
pre g na nc y testi n g) will be prese nte d i n listi n gs.   I n a d diti o n t o t he res ults, t hese listi n gs will 
prese nt t he n or mal ra n ge, t o xicit y gra de, a n d cli nical assess me nt ( N or mal; A b n or mal, b ut n ot 
cli nicall y si g nifica nt; A b n or mal, cli nicall y si g nifica nt) ass ociate d wit h e val uati o ns.   
1 0. 3.  
Tr a nsf usi o n or Gr o wt h F act or S u p p ort  
T he i nci de nce of bl o o d tra nsf usi o n ( platelets, re d bl o o d cells/ w h ole bl o o d ) or gr o wt h fact or 
s u p p ort  will be s u m mari ze d ..  
Data o n tra nsf usi o ns will be prese nte d i n listi n gs.   


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 2 6 of 2 8 
C O N FI D E N TI A L  
 
 
1 0. 4.  
Vit al Si g ns  
Vital si g n res ults ( bl o o d press ure, p ulse, a n d te m perat ure) will be s u m marize d descri pti vel y f or 
eac h sc he d ule d pr ot oc ol ti me p oi nt.  C ha n ges will be calc ulate d relati ve t o t he assess me nts at 
baseli ne.  
Data o n vital si g ns will be prese nte d i n listi n gs.  
1 0. 5.  
Ot h er S afet y Me as ures  
Data o n E C O G perf or ma nce stat us d uri n g t he trial will be prese nte d i n a listi n g . 
1 1.  
C LI NI C A L P H A R M A C O L O G Y A N A L Y S E S  
N o ne 
1 2.  
O T H E R A N A L Y S E S  
N ot a p plica ble.  
1 3.  
D A T A H A N D LI N G C O N V E N TI O N S  
A nal yses will be perf or me d usi n g S A S ® [ S A S I nstit ute 2 0 1 1] Versi o n 9. 3 or hi g her. 
T he cli nical data base will be l oc ke d pri or t o t he i nitiati o n of t he Sta ge 1 statistical a nal yses. A 
data base l oc k is defi ne d as a sta ble data base t hat ca n be a nal yze d a n d re p orte d. C ha n ges t o a 
l oc ke d data base m ust be a ut h orize d i n writi n g b y t he st u d y s p o ns or 
 
 
T he data c o n ve nti o ns i ncl u de t he f oll o wi n g. 
•  Data will be descri be d a n d s u m marize d b y st u d y sta ge ( Sta ge 1 or Sta ge 2), Sta ge 1 
c o h ort (starti n g d ose le vel a n d sc he d ule) , or Sta ge 2 c o h ort ( disease t y pe). 
•  S u m mar y ta bles f or c o nti n u o us varia bles will c o ntai n t he f oll o wi n g statistics: N 
( n u m ber of s u bjects i n t he p o p ulati o n); n ( n u m ber of s u bjects wit h data f or t hat 
varia ble ); mea n; sta n dar d de viati o n; me dia n; mi ni m u m; a n d ma xi m u m. Selecte d 
statistics ma y als o i ncl u de 2 si de d 9 5 % n or mal a p pr o xi mati o n c o nfi de nce i nter vals 
( CI) o n t he mea n. 
•  S u m mar y ta bles f or cate g orical varia bles will i ncl u de: N ( n u m ber of s u bjects i n t he 
de n o mi nat or); n ( n u m ber of s u bjects i n t he n u merat or); a n d perce nt. Selecte d 
statistics als o ma y i ncl u de 2-si de d 9 5 % CIs f or t he perce nt, calc ulate d usi n g t he 
C L = A G R E S TI C O U L L o pti o n i n S A S P R O C F R E Q.  


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 2 7 of 2 8 
C O N FI D E N TI A L  
 
 
•  T he baseli ne val ue f or a gi ve n para meter is t he last val ue pri or t o t he first d ose. A 
val ue is c o nsi dere d t o be p ost- baseli ne if it is o btai ne d after t he first d ose. A val ue is 
c o nsi dere d t o be p ost d ose o n a gi ve n c ycle da y if it is o btai ne d after t he d ose is 
a d mi nistere d o n t hat da y. 
•  Data fr o m all st u d y ce nters will be p o ole d f or all a nal yses.  
•  U nless ot her wise s pecifie d, statistical testi n g will be 2-si de d at a n o mi nal 0. 0 5 le vel 
of si g nifica nce.  
•  St u d y da y is defi ne d as cale n dar date – date of first treat me nt + 1 if t he cale n dar date 
is o n or after t he date of first treat me nt, a n d cale n dar date – date of first treat me nt if 
t he cale n dar date is bef ore t he date of first treat me nt 
•  Meas ure me nts fr o m u nsc he d ule d visits will be i ncl u de d i n listi n gs, b ut n ot s u m mar y 
ta bles. 
•  Missi n g data c o n ve nti o ns f or i n di vi d ual e n d p oi nts are descri be d i n t he S A P secti o n 
f or t he e n d p oi nt. 
•  A d diti o nal e x pl orat or y a nal yses ma y be perf or me d as dee me d a p pr o priate after 
re vie w of t he pre-s pecifie d a nal yses. L o g-tra nsf or mati o ns or n o n para metric tests ma y 
be a p plie d t o meas ure me nts dis pla yi n g a si g nifica nt de gree of n o n- n or malit y.  
•  Listi n g s will be pr o vi de d f or all data c ollecte d i n t he e C R F.  
 
1 4.  
R E P O R TI N G C O N V E N TI O N S 
T he ta ble, listi n g a n d fi g ure re p orti n g la y o ut will be detaile d i n t he c o m pa ni o n d oc u me nt 
K O -TI P - 0 0 3 S afety T a ble, Listi n g  a n d Fi g ure S hells . 
1 5.  
C H A N G E S I N T H E S T A TI S TI C A L M E T H O D S F R O M T H O S E 
S T A T E D I N T H E P R O T O C O L  
N o ne.   
1 6.  
R E F E R E N C E S  
N ote: T he f oll o wi n g secti o ns ma y be create d as se parate d oc u me nts.  


Clie nt C o nfi de ntial 
Statistical A nal ysis Pla n Versi o n:  1 
Pr ot oc ol K O - TI P-0 0 3  
 
 
Pa ge 2 8 of 2 8 
C O N FI D E N TI A L  
 
 
1 7.  
T A B L E S, FI G U R E S, LI S TI N G S  
Ta bles, listi n gs a n d, if a p plica ble, fi g ures will be ge nerate d acc or di n g t o t he c o m pa ni o n 
d oc u me nt w hic h details t he la y o ut of t he o ut p ut. Mi n or st yle de viati o n fr o m s pecificati o n defi ne d 
i n t he s hell d oc u me nt i n t he fi nal pr o d ucti o n is per missi ble.